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Abstract 
Background and aims: Long QT syndrome (LQTS) is an inherent cardiac disorder causing 
severe arrhythmias due to mutations in cardiac ion channel genes. Four founder mutations 
causing LQTS have been identified from Finland and they disrupt functions of cardiac 
potassium ion channels. The aim of this study was to characterize expressions of ion channel 
genes or their allelic expression variation in three different experiments by using qPCR. In 
cell line characterization experiment was evaluated applicability of cell lysis -based 
genotyping method to characterize cardiac cell lines. The aim of the second experiment was to 
evaluate impacts of allelic expression differences on disease phenotype variation and 
development. The last experiment was used for examining capacity of single-cell qPCR 
method to detect specific gene expression within single cardiomyocytes. 
Methods: qPCR was used to detect mRNA levels of ion channel genes or structural genes 
within LQTS-specific cardiomyocytes. The TaqMan® Sample-to-SNP™ Kit was tested in 
order to characterize KCNQ1 mutated heterozygous cardiac cell lines. Allelic imbalance 
determination was performed using plasmid-derived standard curve method for each Finnish 
founder mutations. The Single cell-to-CT™ Kit was used to detect expression of TNNT2 at 
the single cell level and cell population level.  
Results: The used cell lysis -based genotyping method succeeded to characterize cardiac cell 
lines and any disruption was not detected during analyses. Allelic imbalance determination 
study revealed that KCNQ1-FinA and KCNQ1-FinB specific cardiomyocytes expressed 
alleles of KCNQ1 with allelic ratios 3:1 indicating that expression of wild type allele was 
three-fold as compared to expression of mutant allele within these LQT1-specific cells. The 
Single cell-to-CT™ Kit did not manage to detect gene expression of TNNT2 within single cell 
samples and its expression at population level was also reduced. 
Conclusions: The detected allelic ratio 3:1 (WT:MUT) within KCNQ1-FinA and KCNQ1-
FinB mutated cardiomyocytes could result in milder phenotypic effects due to that higher 
expression of wild type alleles may suppress effects of mutations. Milder phenotypic effects 
have been thought to be reason for unique enrichment of founder mutations among Finnish 
population. Therefore, allelic imbalance occurring in disease-causing genes can be a 
significant disease phenotype modifier. To validate this hypothesis, larger study population of 
mutation carriers with high phenotypic variation is needed. If correlation between allelic 
imbalance and phenotypic variation is detected, the allelic expression variation might be 
confirmed to be one explaining genetic factor to affect phenotypic variation. 
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Tiivistelmä 
Tutkimuksen tausta ja tavoitteet: Pitkä QT oireyhtymä on vakavia rytmihäiriöitä aiheuttava 
perinnöllinen sairaus, joka johtuu mutaatioista sydänlihassolun ionikanavageeneissä. 
Suomessa vallitsee neljä pitkä QT oireyhtymää aiheuttavaa perustajamutaatiota, jotka 
heikentävät sydänlihassolujen kalium-ionikanavien toimintaa. Tämän tutkimuksen tavoitteena 
oli karakterisoida LQTS-spesifisten sydänlihassolujen ionikanavageenien ilmentymistä tai 
niiden alleeli-ilmentymiseroja hyödyntämällä qPCR-menetelmää kolmessa erillisessä työssä. 
Ensimmäisessä työssä arvioitiin solulyysaukseen perustuvan genotyyppausmenetelmän 
soveltuvuutta sydänsolulinjojen karakterisointiin. Toisen työn tavoitteena oli arvioida alleeli-
ilmentymiserojen vaikutuksia tautifenotyypin vaihteluun ja kehittymiseen. Kolmannen työn 
tarkoituksena oli tutkia yksisolu-qPCR-menetelmän tehokkuutta havainnoida yksittäisten 
sydänlihassolujen geeni-ilmentymistä.  
Menetelmät: qPCR-menetelmää käytettiin jokaisessa työssä mittaamaan ionikanavageenien 
tai rakennegeenien mRNA-tasoja LQTS-spesifisistä sydänlihassoluista. Ensimmäisessä työssä 
käytettiin TaqMan® Sample-to-SNP™ Kit -menetelmää karakterisoimaan heterotsygoottisia 
sydänsolulinjoja, joissa oli KCNQ1-geenin mutaatio. Alleeli-ilmentymisvaihteluun perustuva 
tutkimus suoritettiin plasmideista tuotetun standardikuvaajan avulla jokaiselle Suomessa 
vallitsevalle perustajamutaatiolle. Viimeisessä työssä käytettiin Single cell-to-CT™ Kit -
menetelmää, jonka avulla mitattiin TNNT2-geenin ilmentymistä sekä yksittäissolu- että 
solupopulaatiotasolla. 
Tulokset: Ensimmäisen työn tuloksista pääteltiin, että solulyysaukseen perustuva 
genotyyppausmenetelmä soveltuu sydänsolulinjojen karakterisointiin, eikä analyysiä 
häiritseviä tekijöitä havaittu. Alleeli-ilmentymiseen perustuva tutkimus paljasti, että KCNQ1-
FinA ja KCNQ1-FinB spesifisissä sydänlihassoluissa KCNQ1-geenin alleelit ilmentyivät 3:1-
suhteessa, joka tarkoitti sitä, että villityyppialleelien ilmentyminen oli kolminkertainen 
verrattuna mutanttialleelien ilmentymiseen näissä LQT1-spesifisissä soluissa. Single cell-to-
CT™ Kit -menetelmällä ei onnistuttu havainnoimaan TNNT2-geenin ilmentymistä 
yksittäissolutasolla ja solupopulaatiotasolla sen ilmentyminen oli myös heikkoa. 
Johtopäätökset: Havaittu alleeli-ilmentymissuhde 3:1 (WT:MUT) KCNQ1-FinA ja KCNQ1-
FinB mutatoituneissa sydänlihassoluissa voisi johtaa mutaatioiden heikentyneisiin 
fenotyyppivaikutuksiin, koska villityyppialleelin voimakkaampi ilmentyminen saattaa 
heikentää mutaatioiden vaikutuksia. Aiemmin on arveltu, että perustajamutaatioiden heikompi 
fenotyyppivaikutus on johtanut niiden yleistymiseen Suomessa. Tällöin 
taudinaiheuttajageenien alleelien ilmentymiserot saattavat vaikuttaa merkittävästi 
tautifenotyyppiin. Tämän varmistamiseksi on kuitenkin tutkittava alleeli-ilmentymiserot 
suuremmasta populaatiosta mutaationkantajia, joilla on havaittu suuri fenotyyppivaihtelu. Jos 
alleeli-imbalanssin ja fenotyypin välillä havaitaan korrelaatiota, voitaisiin alleeli-imbalanssi 
varmistaa yhdeksi fenotyyppivaihtelua selittäväksi geneettiseksi tekijäksi.  
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1. Introduction 
Long QT syndrome (LQTS) is a cardiac channelopathy causing life-threatening arrhythmias 
that can lead to sudden death at the young age (Roden et al., 2008).  LQTS-associated 
mutations affect electrical function of cardiac ion channels resulting in delayed repolarization 
within cardiomyocytes that is observed as prolonged QT interval on the electrocardiogram 
measured from mutation carriers. There has been observed significant phenotypic variation 
and incomplete disease penetrance among LQTS patients that have led to suggestions that 
various genetic or non-genetic factors may modify disease phenotypes (Fodstad et al., 2004; 
Lahti et al., 2012). The unique enrichment of LQTS-specific founder mutations among 
Finnish population (Fodstad et al., 2004) offers enormous opportunity to evaluate factors 
affecting LQTS development and phenotypic variation.  
 
The iPSC technology developed by Takahashi et al. (2007) produce a revolutionary approach 
to identify disease mechanisms in a novel way by allowing generation of disease-specific cell 
types derived from disease-causing mutation carriers, and thereby enabling more accurate in 
vitro disease modelling than was able with previous models. Many robust differentiation 
protocols have been developed to generate functional cardiomyocytes from patient-specific 
iPSCs (Mummery et al., 2012). They have increased generation of LQTS-specific disease 
models for allowing efficient evaluations of disease phenotypic features and drug 
responsiveness within cardiomyocytes containing various LQTS-related mutations (Itzhaki et 
al., 2011; Matsa et al., 2011). Furthermore, using iPSC-derived LQTS-specific 
cardiomyocytes, the unknown cellular mechanisms that cause variability for disease 
phenotypic features among patients can be examined.  
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2. Review of literature 
2.1. Cardiac ion channels involving in development of action   
potential 
In the sinoatrial node of the heart, pacemaker cardiomyocytes are able to spontaneously 
depolarize themselves developing electrical impulse that conducts throughout the heart 
(Giudicessi and Ackerman, 2012). Conduction system regulates motion of electrical impulse 
to the myocardium where electrical excitation initiates action potential development within 
cardiomyocytes (Bezzina and Wilde, 2007; Grant, 2009). Gap junctions between 
cardiomyocytes enable effective propagation of electrical excitation leading to contraction of 
the myocardium in order to ensure proper blood pumping ability of the heart (Giudicessi and 
Ackerman, 2012). This electrical function is detected on the surface electrocardiogram (ECG) 
(Bezzina and Wilde, 2007). On the ECG, P-wave indicates contraction of atria from which 
electrical impulse conducts along Purkinje fibers to ventricles. Depolarization of the 
ventricles forms QRS-complex and ventricular repolarization is detected as T-wave.  
 
Cardiac ion channels and their rapid depolarizing and slow repolarizing ion currents (figure 
1.) generate action potential in a response to electrical impulse. Action potential consists of 
resting (phase 4), depolarization (phase 0), transient repolarization (phase 1), plateau (phase 
2) and repolarization (phase 3) steps (figure 1.) in which ion conductance through cardiac ion 
channels occurs along electrochemical gradients (Grant, 2009). The conduction of electrical 
impulse to the myocardium initiates depolarization of cardiomyocytes by activating sodium 
ion channels that lead to influx of Na
+
 ions (Giudicessi and Ackerman, 2012). During 
depolarization phase, negative resting membrane potential becomes more positive due to 
increased intracellular Na
+
 concentration via inward INa current. Depolarization is followed by 
a short, transient repolarization phase caused by outward potassium current, Ito through 
KCND3-encoded channels (Giudicessi and Ackerman, 2012). During the plateau phase, 
maintenance of positive membrane potential occur via inward current of Ca
2+
 ions and 
outward current of K
+
 ions through L-type Ca
2+
 ion channels and delayed rectifier K
+
 ion 
channels, respectively (Roden et al., 2002; Bezzina and Wilde, 2007). Increased intracellular 
Ca
2+
 concentration induces releasing of stored calcium ions from sarcoplasmic reticulum 
through ryanodine receptors (RYR2) (Bezzina and Wilde, 2007) and thereby further 
increasing Ca
2+
 concentration causes contraction of sarcomeres within cardiomyocytes.  
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Figure 1. Schematic picture of a cardiomyocyte and its cardiac ion channels which involve in 
action potential development. Ion currents conducted by different cardiac ion channels during 
ventricular action potential are represented in the figure on the right. Sequential ion 
conductions of the channels ensure appropriate electrical function of a cardiomyocyte leading 
to its contraction. The figures were modified from origin Bezzina and Wilde, 2007. 
 
Activation of outward potassium ion channels occurs during plateau phase and they are 
responsible for cardiomyocyte repolarization (Bezzina and Wilde, 2007). Repolarizing K
+
 ion 
currents restore negative resting membrane potential that is -80 mV in atrial and -85 mV in 
ventricular cardiomyocytes (Giudicessi and Ackerman, 2012). In addition, variation in action 
potential durations (APD) and configurations are seen between nodal, atrial and ventricular 
cardiomyocytes due to different functional ion channels and proteins associated with them 
(Roden et al., 2002). Termination of repolarization and maintenance of resting membrane 
potential are occurred by outward K
+
 ion current, IK1 through inward rectifier potassium 
channel encoded by KCNJ2 gene (Tristani-Firouzi et al., 2002; Bezzina and Wilde, 2007). 
When resting membrane potential has recovered and contraction has relaxed, new electrical 
excitation can initiate development of action potential within myocardium. Pacemaker 
current, If depolarizes nodal cardiomyocytes in the sinoatrial node, leading to generation of 
new electrical impulse (Amin et al., 2010). If-conducting channels are hyperpolarization-
activated cyclic nucleotide-gated (HCN) channels indicating that hyperpolarization triggers 
their activation and intracellular cyclic adenosine monophosphate (cAMP) levels regulate 
their current amplitudes (Amin et al., 2010).  
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Voltage-gated cardiac Na
+
 and Ca
2+
 ion channels conduct depolarizing ion currents, INa and 
ICa, respectively, which change normal negative membrane potential to more positive during 
action potential (Giudicessi and Ackerman, 2012). These channels share structural similarity. 
Both channels compose of single α-subunit encoded by SCN5A or CACNA1C, respectively, 
that contains four homologous domains and each includes six transmembrane segments 
(Grant, 2009; Amin et al., 2010). Pore-forming loop locates between S5 and S6 segments in 
each domain and its amino acid content specifies selectivity of ion conductance (Bezzina and 
Wilde, 2007). Voltage-gating of cardiac ion channels is based on voltage sensing S4 segments 
which react to changes in membrane potential by altering open and close conformations of 
channel due to their content of positively charged amino acid residues, including arginine or 
lysine in every third position (Roden et al., 2002; Grant, 2009). 
  
In cardiomyocytes, two potassium ion channels are active in repolarization phase and they 
regulate action potential duration (APD) (Bezzina and Wilde, 2007). KCNQ1 gene encodes α-
subunits of slowly activating delayed rectifier K
+
 ion channels that conduct IKs currents 
(Vincent, 1998; Jespersen et al., 2005). The other repolarizing ion current is IKr conducted by 
rapidly activating delayed rectifier K
+
 ion channels that compose of α-subunits encoded by 
KCNH2 gene (known also as human ether-a-go-go-related gene, HERG) (Vincent, 1998; 
Roden et al., 2002). Structures of these voltage-gated potassium ion channels (figure 2.) 
resemble Na
+
 and Ca
2+
 ion channels but they contain four α-subunits assembled to tetrameric 
structure (Bezzina and Wilde, 2007). Each α-subunit has six transmembrane segments that 
have similar functions as described above. Four α-subunits organize to form pore region to the 
middle of ion channel that is surrounded by α-helices of S6 segments (Bezzina and Wilde, 
2007). When the channel is inactivated, S6 segments have oriented across each other and 
prevent K
+
 ion permeation (Sanguinetti and Tristani-Firouzi, 2006). Depolarization induces 
movement of S6 segments resulting in increased size of pore region allowing ion conduction. 
The amino acid contents responsible for K
+
 ion selectivities are Gly-Tyr-Gly (Grant, 2009) 
and Ser-Val-Gly-Phe-Gly (Sanguinetti and Tristani-Firouzi, 2006) in KCNQ1 channel and 
HERG channel, respectively.  
 
Both repolarizing cardiac K
+
 ion channels interact with auxiliary β-subunits that are required 
for properly formed functional channels. KCNE1-encoded MinK β-subunit interacts with 
5 
 
slowly activating delayed rectifier K
+
 ion channel (Splawski et al., 1997) and modifies its 
gating properties by slowing channel activation and deactivation and reducing inactivation 
that result in increased IKs current (Jespersen et al., 2005). The suggested number of 
interacting MinK subunits with KCNQ1 channel is two or four locating close to pore-forming 
region (Jespersen et al., 2005). KCNE2-encoded MiRP1 (MinK-related peptide-1) interacts 
with rapidly activating delayed rectifier K
+
 ion channel (Abbott et al., 1999). MiRP1 alter 
HERG channel gating by slowing activation and increasing deactivation rates. Therefore, 
HERG channels open in a response to higher positive membrane potential caused by 
depolarization and return more rapidly to deactivate state after repolarization (Abbott et al., 
1999). MinK and MiRP1 share significant sequence similarity, reflecting to their functional 
similarities among K
+
 ion channels (Abbott et al., 1999; Jespersen et al., 2005). For example, 
MinK β-subunit is able to interact with HERG channel as well, but it cannot alter that channel 
gating similarly than MiRP1 does (Abbott et al., 1999). 
 
Many cardiac ion channels are closed by deactivation, indicating that open channels close 
rapidly when the membrane potential is near to threshold potential (Grant, 2009). The 
deactivation is the most critical process because if it has accelerated or slowed the influence 
reflects directly to APD (Abbott et al., 1999; Clancy and Rudy, 2001). Gating properties of 
HERG channels are unique as compared to other cardiac ion channels (Clancy and Rudy, 
2001; Sanguinetti and Tristani-Firouzi, 2006). Cardiomyocyte depolarization induces 
extremely rapid transition of HERG channels from open state to inactivated state. During 
plateau phase, positive membrane potential is increasing and that triggers opening of 
inactivated channels allowing greater amplitude of IKr current and initiation of cardiomyocyte 
repolarization. Deactivation of HERG channels occurs slowly for ensuring sufficient 
repolarization. Similar rapid inactivation process does not occur among other cardiac ion 
channels during action potential (Amin et al., 2010). 
 
Insufficient or abnormal cardiac ion channel function can lead to development of arrhythmic 
disease state that have been characterized within various disorders, such as long QT 
syndrome, short QT syndrome, Brugada syndrome and catecholaminergic polymorphic 
ventricular tachycardia (CPVT) (Kontula, 2005; Bezzina and Wilde, 2007). Structural 
abnormalities or defective electrical function affect conductance ability of ion channels
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Figure 2. Structure of voltage-gated potassium ion channel in cardiomyocytes. K
+
 ion 
channels consist of four α-subunits containing six transmembrane segments. The pore region 
formed by assembled α-subunits is surrounded by loop structures between S5 and S6 
segments. S4 segment is responsible for sensing voltage changes leading to channel opening 
or closing during action potential. Similar membrane organizations are observed in sodium 
and calcium ion channels, but they are composed by single α-subunit containing four 
domains, resembling represented α-subunit. The figure was modified from the origin Bezzina 
and Wilde, 2007.  
 
resulting in altered action potential within cardiomyocytes and increased risk of arrhythmias 
(Roden et al., 2002). Early after-depolarizations (EADs) and delayed after-depolarizations 
(DADs) are common mechanisms to develop arrhythmias caused by altered ion channel 
functions during action potential. Prolonged action potential duration can reactivate L-type 
Ca
2+
 ion channels leading to spontaneous depolarization of cardiomyocytes and development 
of EADs (Vincent, 1998; Clancy and Rudy, 2001; Amin et al., 2010). Generation of DADs 
can occur if increased intracellular Ca
2+
 concentration, due to the reactivated channels, causes 
release of Ca
2+
 ions from sarcoplasmic reticulum in order to prepare cardiomyocyte to 
contract (Saucermann et al., 2004), or if Na
+
 ion channels become activated during resting 
phase due to activated Na
+
/Ca
2+
-exchangers which remove excess intracellular calcium while 
increase intracellular sodium levels (Amin et al., 2010). EADs and DADs may trigger 
development of ventricular tachyarrhythmias that can lead to sudden cardiac death (Vincent, 
1998). 
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2.2. Long QT syndrome 
Long QT syndrome is a congenital heart disease causing severe arrhythmias associated with 
increased risk of sudden death at the young age (Vincent, 1998; Roden, 2008). The LQTS is 
characterized by prolonged QT interval observed on the ECG measurement. The QT interval 
describes development of ventricular action potential and its duration (Grant, 2009) and 
therefore LQTS induces prolongation of ventricular repolarization phase within 
cardiomyocytes. LQTS-associated ventricular arrhythmias and specific polymorphic 
ventricular tachycardia, known as torsades de pointes (TdP), can lead to ventricular 
fibrillation and sudden death caused by cardiac arrest (Vincent, 1998; Roden, 2008; Toivonen 
et al., 2008). Common clinical manifestations related to LQTS are syncopes and seizures 
resulted from cardiac events that are usually detected at childhood or adolescence (Vincent, 
1998).  
 
The most prevalent form of LQTS is autosomal dominantly inherent Romano-Ward syndrome 
(RWS) (Splawski et al., 2000; Bezzina and Wilde, 2007) which clinical prevalence in 
worldwide ranges between 1:5000 – 1:10000 (Fodstad et al., 2004; Marjamaa et al., 2009), 
but in Finland the clinical prevalence is 1:3000 (Toivonen et al., 2008) that is relatively higher 
than has been characterized within other populations. The RWS is caused by heterozygous 
mutations in genes encoding subunits of cardiac ion channels or proteins which assist their 
functions. LQTS-associated gene mutations either increase depolarizing inward INa or ICa 
currents or reduce repolarizing outward IKs, IKr or IK1 currents that result in prolonged 
ventricular repolarization and increased APD leading to prolongation of QT interval seen on 
patient’s ECG (Bezzina and Wilde, 2007; Giudicessi and Ackerman, 2012). More than 400 
LQTS-causing mutations have been identified (Ackerman, 2005) and 75 % of the diagnosed 
patients have mutation in one of the KCNQ1, KCNH2 or SCN5A genes (Marjamaa et al., 
2009) which cause the most common subtypes of LQTS: LQT1, LQT2 and LQT3, 
respectively. Romano-Ward syndrome type LQTS has been divided into twelve subtypes 
(Amin et al., 2010) according to the gene affected by disease-causing mutation (table 1). 
Eight of the subtypes are caused by mutations in genes encoding either α- or β-subunits of the 
cardiac ion channels. The rest four subtypes have been identified to be caused by mutations in 
proteins assisting ion channel functions (table 1.). Ion channel defects caused by mutations 
are primary affecting the function of the heart, but subtypes LQT7 (Tristani-Firouzi et al., 
2002) and LQT8 (Splawski et al., 2004) are characterized by distinct physiological and 
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developmental dysfunctions in multiple organs besides to cardiac events and prolonged QT 
interval. Each subtype produces different T-wave morphology on the ECG and it can be used 
for their identification or prediction of underlying disease-causing gene mutations (Vincent, 
1998; Ackerman, 2005). 
 
The more rare form of LQTS is autosomal recessively inherent Jervell and Lange-Nielsen 
syndrome (JLNS) having incidence as low as 1:500 000 (Splawski et al., 1997). The JLNS is 
caused by homozygous mutations in KCNQ1 (Neyroud et al., 1997; Splawski et al., 1997) or 
KCNE1 (Schulze-Bahr et al., 1997) genes. Compared with RWS, disease phenotype in JLNS 
is more severe, including sensorineural deafness and more increased risk of sudden death 
(Neyroud et al., 1997) due to that homozygous mutations cause significant suppression of 
channel subunit expression (Schmitt et al., 2000).  In addition to cardiac expression of 
KCNQ1 and KCNE1genes, they are expressed in marginal cells of stria vascularis in inner ear 
where ion channels encoded by them transport K
+
 ions into endolymph (Neyroud et al., 1997). 
Therefore impaired ion transportation of mutated channels cause decreased K
+
 concentration 
of the endolymph lead to inner ear defects. 
 
Diagnosis of long QT syndrome is based on measured time of QT interval by the ECG and 
experienced LQTS-related symptoms, such as palpitations, ventricular arrhythmias, syncope 
caused by physical effort, stress or unexplainable reason, undetected structural aberration in 
heart, or some family member has LQTS diagnosis (Vincent, 1998; Bezzina and Wilde, 2007; 
Saenen and Vrints, 2008; Toivonen et al., 2008). However, prolonged QT interval cannot be 
used alone for basis of LQTS diagnosis because even 40-50 % mutation carriers do not have 
difference in length of QT interval when compared to healthy people (Vincent, 1998). QT 
interval corrected with heart rate (QTc) is better parameter than QT interval directly detected 
on the ECG for evaluating the prolongation due to that the heart rate impacts significantly on 
the length of QT interval (Bezzina and Wilde, 2007). Thereby, differences in heart rhythms 
within population can be compensated by using QTc values. To calculate QTc values Bazett’s 
formula is used: QTc (ms) = QT (ms) / √RR (s). Prolonged QTc is defined to be over 450 ms 
in men and over 460 ms in women (Giudicessi and Ackerman, 2012). However, the only 
option to verify diagnosis is genetic analysis in order to identify underlying gene mutation 
(Toivonen et al., 2008) because high variability of symptoms among LQTS patients
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 Table 1. Long QT syndrome subtypes. 
Long QT 
syndrome 
subtype 
Gene and 
its locus
*
 
Protein and its function Pathological mechanism of mutation 
for ion channel function 
References 
LQT1 KCNQ1, 
11p15.5 
KV7.1, 
α-subunit of slowly 
activating delayed 
rectifier K
+
 ion channel 
Decrease outward  IKs by many 
mechanisms, e.g. affecting assembly 
ability of α-subunit, altering gating 
properties and reducing trafficking 
Piippo  
et al., 2001; 
Moretti  
et al., 2010  
LQT2 KCNH2, 
7q36.1 
KV11.1,  
α-subunit of rapidly 
activating delayed 
rectifier K
+
 ion channel 
Decrease outward IKr by accelerating 
deactivation rate 
Fodstad  
et al., 2006 
LQT3 SCN5A, 
3p21 
NaV1.5,  
α-subunit of Na+ ion 
channel 
Increase inward INa by delaying rapid 
channel inactivation and causing 
reopenings at depolarization phase 
Splawski 
et al., 2000 
LQT4 ANK2, 
4q25-q27 
Ankyrin-B,  
membrane adapter 
protein 
Reduced ankyrin-B decrease protein 
levels and cellular organization of 
Na/K ATPase, Na/Ca exchanger and 
inositol-1,4,5-trisphosphate receptor 
resulting in increased intracellular Ca
2+
 
concentrations 
Mohler 
et al., 2003 
LQT5 KCNE1,  
21q22.12 
MinK,  
β-subunit of KCNQ1-
encoded ion channel 
Decrease outward IKs by increasing 
required voltage for channel activation 
and accelerate deactivation rate 
Splawski 
et al., 1997 
LQT6 KCNE2,  
21q22.12 
MiRP1,  
β-subunit of KCNH2-
encoded ion channel 
Decrease outward IKr by increasing 
required voltage for channel activation 
and accelerate deactivation rate 
Abbott  
et al., 1999 
LQT7 
(Andersen 
syndrome) 
KCNJ2,  
17q24.3 
Kir2.1, 
α-subunit of inward 
rectifier K
+
 ion channel 
Decrease outward IK1 by causing 
reduction in extracellular K
+
 
concentration and prolongation of 
terminal repolarization 
Tristani-
Firouzi 
et al., 2002 
LQT8 
(Timothy 
syndrome) 
CACNA1C, 
12p13.3 
CaV1.2, 
α-subunit of L-type Ca2+ 
ion channel 
Increase inward ICa by slowing channel 
inactivation rate resulting in increased 
intracellular Ca
2+
 concentration 
Splawski 
et al., 2004 
LQT9  CAV3,  
3p25 
Caveolin-3, 
component of caveolae 
which associates with 
Na
+
 ion channels 
Increase inward INa by causing gain of 
function of Na
+
 ion channel 
Vatta 
et al., 2006 
LQT10 SCN4B,  
11q23.3 
β4,  
one of the auxiliary β-
subunits of Na
+
 ion 
channel 
Increase inward INa by modifying 
channel inactivation 
Medeiros-
Domingo 
et al., 2007 
LQT11 AKAP9,  
7q21-q22 
Yotiao,  
mediate 
phosphorylation of 
KCNQ1-encoded K
+
 ion 
channel with protein 
kinase A 
Disrupted phosphorylation of KCNQ1 
channel reduces IKs during β-
adrenergic stimulation 
Chen  
et al., 2007 
LQT12 SNTA1,  
20q11.2 
α1-syntrophin,  
regulates interaction 
between NaV1.5 and 
nNOS-PMCA4b 
complex 
Increase inward INa by preventing 
function of PMCA4b resulting in 
increased direct S-nitrosylation of 
NaV1.5 
Ueda 
et al., 2008 
*
 indicates that data of genetic loci has been searched from Gene database of NCBI 
(http://www.ncbi.nlm.nih.gov/gene, cited on 5.4.2015). 
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complicates identification of robust disease phenotype. In addition, due to highly family 
specific feature of LQTS-associated mutations (Fodstad et al., 2004), genetic testing allows 
screening of symptomless mutation carriers within families with diagnosed LQTS.  
 
The treatment of LQTS patients is decided according to occurrence of cardiac events. All 
symptomatic patients, and usually many asymptomatic patients too, are treated with β-
blockers in order to prevent cardiac events and TdPs, but the highest benefit of this treatment 
is achieved in LQT1 due to its associated β-adrenergic stimulus trigger (Vincent, 1998; 
Bezzina and Wilde, 2007). The common treatments for patients having severe cardiac events 
regardless of β-blocker medication are pacemaker or implantable cardiac defibrillator (Saenen 
and Vrints, 2008) which maintain the normal heart rhythm and inhibit occurrence of 
ventricular arrhythmias. 
 
Incomplete disease penetrance and phenotypic variations within LQTS patients is 
significantly common (Fodstad et al., 2004; Lahti et al., 2012). Some affected individuals 
have experienced severe cardiac symptoms whereas many patients are completely 
asymptomatic and not even aware that they carry disease-causing mutation (Lahti et al., 
2012). Approximately even half of the diagnosed patients are symptomless (Toivonen et al., 
2008), indicating high variation in the clinical manifestation among diagnosed patients. 
Furthermore, it is typical that disease phenotype varies within family with the same mutation 
in a particular gene (Fodstad et al., 2006). Due to high phenotypic variation and many not 
diagnosed asymptomatic patients, the determination of prevalence is difficult and the risk of 
misdiagnosis increase (Egashira et al., 2012). It has been estimated that the amount of LQTS 
patients with undetected disease-causing mutation is approximately 20 % (Vatta et al., 2006; 
Ueda et al., 2008). There have been suggested that some genetic or non-genetic factors are 
affecting for development of variable disease phenotypes (Piippo et al., 2001; Fodstad et al., 
2006) and their identification could enhance knowledge about factors provoking severe form 
of LQTS or which factors cause completely asymptomatic form.  
 
One type of LQTS is acquired or drug-induced form in which cardiac events are caused by 
QT interval prolonging drugs. These kinds of drugs block IKr currents in HERG potassium ion 
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channels due to their specific structures of extracellular pore region which make them highly 
susceptible to be blocked (Roden et al., 2002; Sanguinetti and Tristani-Firouzi, 2006). Two 
structural features have been identified to increase HERG channel susceptibility (Roden et al., 
2002; Sanguinetti and Tristani-Firouzi, 2006). Lack of prolines in S6 segments result in 
enlarged pore region which is more susceptible for drug blockade when compared to other K
+
 
channels in which prolines cause their twisting and therefore reducing pore region size. 
Second reason is that pore region of HERG channels contain aromatic amino acids (Tyr652 
and Phe656) which can bind with charged or aromatic residues of drugs allowing more 
sustained blockade. Many cardiac and non-cardiac, such as some antihistamine, antibiotic and 
psychotropic (Vincent, 1998), drugs are able to prevent ion conducting function of HERG 
channel. Defective function resulted from drug blockade lead to increased risk of 
development of arrhythmias and other cardiac events (Lahti et al., 2012). That is why LQTS 
patients have to avoid drugs that could prolong QT interval. 
2.2.1. Mutations causing long QT syndrome 
LQTS-associated mutations are located in genes encoding α- or β-subunits of cardiac ion 
channels (Splawski et al., 2000) or their auxiliary proteins, such as ankyrin-B (Mohler et al., 
2003) and Yotiao (Chen et al., 2007). Until now, twelve genes have been identified to 
increase susceptibility for LQTS when containing specific mutations (Amin et al., 2010) by 
either reducing repolarizing K
+
 currents or increasing depolarizing Na
+
 or Ca
2+
 currents that 
result in abnormal electrical function of cardiomyocytes and increased risk of development of 
arrhythmias (Bezzina and Wilde, 2007). Although strong family history is related to LQTS 
and many mutations are highly family specific, LQTS-causing rare de novo mutations have 
also been identified (Splawski et al., 2004; Vatta et al., 2006). Loss-of-function mutations 
with dominant negative effects are common among LQTS-causing mutations, especially 
within K
+
 ion channels, and usually those cause significant reductions of affected ion currents 
(Clancy and Rudy, 2001), and therefore higher risk of severe disease phenotype (Moss et al., 
2007).  
 
Important property of KCNQ1 channel is the response for β-adrenergic stimuli and 
accelerated heart rate resulted from e.g. physical exercise by increasing repolarizing K
+
 
current amplitude (Bezzina and Wilde, 2007; Giudicessi and Ackerman, 2012). However, 
mutated channels are not able to react sufficiently to increased depolarizing currents caused 
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by β-adrenergic stimulation, and that lead to occurrence of LQT1-related cardiac symptoms 
during exercise or emotional stress and not typically seen shortening of QT interval. 
 
There are three main mechanisms how LQTS-associated mutations affect functions of cardiac 
ion channels. Mutations may cause defective assembly ability of subunits resulting in 
impaired formation of functional channels (Schmitt et al., 2000). This mechanism has been 
identified from K
+
 ion channels having tetrameric structure of four α-subunits. When allelic 
expression of mutant and wild type alleles are equal, the reduction of K
+
 current could be 
expected to be 50 % (Bezzina and Wilde, 2007). However, many LQTS-causing mutations 
have dominant negative effects, indicating that only single mutant α-subunit involving in 
channel-forming tetramer can cause channel dysfunction. Therefore reduction of ion current 
could be more than 50 % in mutated channels (Moss et al., 2007; Saenen and Vrints, 2008). 
The other common pathogenic mechanism is altered channel gating or kinetics that affect 
directly to ion conductance of channels (Bezzina and Wilde, 2007). In addition, reduced 
trafficking of mutant subunits from endoplasmic reticulum to cell membrane of 
cardiomyocytes decrease amount of surface expressed channel-forming subunits (Clancy and 
Rudy, 2001; Sanguinetti and Tristani-Firouzi, 2006). Mutations can change protein synthesis 
or folding of translated proteins leading to their impaired trafficking (Sanguinetti and Tristani-
Firouzi, 2006) or mutation can suppress directly the protein trafficking (Moretti et al., 2010). 
For example, defective protein trafficking has been identified to be major reason for abnormal 
function of HERG channels affected by 80-90 % of LQTS-associated KCNH2 gene mutations 
(Giudicessi and Ackerman, 2012).  
 
Risk of occurrence of cardiac events and their severities are significantly dependent on 
mutation type and location within subunits of cardiac ion channels (Giudicessi and Ackerman, 
2012). 72 % of LQTS-associated mutations are missense mutations causing change of single 
amino acid residue in subunit or auxiliary proteins (Splawski et al., 2000). Their phenotypic 
effects are highly dependent on location. If the mutation locates in region that has important 
role in ion channel function, the LQTS-related phenotypic effects are more severe (Toivonen 
et al., 2008). Especially influences of mutation locations within potassium ion channels 
encoded by KCNQ1 and KCNH2 genes have been evaluated (Giudicessi and Ackerman, 
2012). LQT1-causing mutations have been associated with increased risk of cardiac events, 
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more severe disease phenotype and longer QT interval if a mutation locates in transmembrane 
domains or C-terminal part of α-subunit because those parts have effects on gating properties 
and subunit assembly ability, respectively. LQT2-associated mutations increase susceptibility 
for LQTS phenotype if they locate in pore-forming region, including S5 and S6 segments and 
pore-forming loop between them, resulting in altered K
+
 transportation and channel gating 
(Splawski et al., 2000). In addition, N-terminal location of mutation is associated with 
accelerated deactivation of HERG channel (Splawski et al., 2000; Clancy and Rudy, 2001). 
However, mutations that have stronger influence to protein structure (e.g. frame-shift 
mutations, insertions and deletions) cause always severe phenotypes despite of their locations 
(Giudicessi and Ackerman, 2012).  
2.2.1.1. LQTS-associated mutations in Finland 
Four founder mutations that cause long QT syndrome have been identified to be 
predominating in Finland, indicating that 73 % of diagnosed LQTS patients among Finnish 
population carry one of the four disease-causing founder mutation (Fodstad et al., 2004). Two 
of them are located in KCNQ1-encoded α-subunit (figure 3.) and are named as KCNQ1-FinA 
(G589D) (Piippo et al., 2001) and KCNQ1-FinB (IVS7-2A>G) (Fodstad et al., 2006). They 
cause LQT1 subtype that is the most common (71 %) subtype occurring in Finland and 
elsewhere (Fodstad et al., 2004). The remaining two mutations are HERG-FinA (L552S) 
(Piippo et al., 2000) and HERG-FinB (R176W) (Laitinen et al., 2000; Fodstad et al., 2006) 
locating in KCNH2-encoded α-subunit (figure 3.) and causing LQT2 subtype which 
proportion from Finnish LQTS cases is 20-30 % (Fodstad et al., 2004). Marjamaa et al. 
(2009) estimated that the prevalence of founder mutations within Finnish population may be 
even 1:250, indicating their significant enrichment as compared to relatively lower 
prevalences of LQTS-associated mutations in worldwide and other estimations from Finland 
(Fodstad et al., 2004). Despite of high prevalence, only approximately 20-30 % of mutation 
carriers have cardiac events related to LQTS (Marjamaa et al., 2009) and that may be resulted 
from milder effects of founder mutations that have allowed their enrichment within Finnish 
population (Piippo et al., 2001).  
 
KCNQ1-FinA (G589D) is a missense mutation which has position in C-terminal part of the 
KCNQ1 protein. Genetic location of the mutation is in nucleotide 1876 where normally 
occurring guanine has changed to adenine causing substitution of glycine by aspartic acid at
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Figure 3. Locations of four Finnish founder mutations in K
+
 ion channels’ α-subunits encoded 
by KCNQ1 and KCNH2 genes. KCNQ1-FinA and KCNQ1-FinB mutations locate in C-
terminal part of KCNQ1 protein. In HERG protein, locations of HERG-FinA and HERG-
FinB are in S5 segment and N-terminal part, respectively. FinA mutations are marked by red 
and FinB mutations by blue. Other LQTS-causing mutations, represented in the figures, have 
also been identified from Finnish population in the study published by Fodstad et al. (2004). 
K897T in HERG protein is commonly occurring polymorphism identified from Finnish 
population and therefore it is highlighted with green in the figure. The figure was modified 
from the origin Kontula, 2005.  
 
position 589 in KCNQ1 protein (Piippo et al., 2001). This mutation is the most common 
within all four founder mutations (Marjamaa et al., 2009). KCNQ1-encoding α-subunit has C-
terminal subunit assembly domain at position 589-620, that has been identified to be essential 
for formation of functional tetrameric channels (Schmitt et al., 2000). Thus, mutations, such 
as KCNQ1-FinA, in that region cause abnormal function of assembly domain resulting in 
disability of α-subunit to assemble with other subunits generally in dominant negative manner 
(Schmitt et al., 2000; Piippo et al., 2001). Functional in vitro studies have revealed reduction 
of IKs current and increased required voltage for activation in KCNQ1-FinA mutated channels 
when they are expressed with MinK β-subunits (Marjamaa et al., 2009). Commonly detected 
reductions of IKs currents are approximately 50 % (Saucermann et al., 2004). In Finland have 
also been diagnosed few JLNS cases caused by homozygous KCNQ1-FinA mutations, but 
their prevalence is significantly lower than RWS caused by heterozygous mutations (Piippo et 
al., 2001). 
 
Other mechanism that develops arrhythmic phenotype in LQT1 due to G589D-mutated 
KCNQ1 has been related to prevented β-adrenergic stimulation of mutant channel 
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(Saucermann et al., 2004). C-terminal location of KCNQ1-FinA mutation in α-subunits 
disrupts interaction between KCNQ1 channel and A-kinase anchoring protein (AKAP), 
Yotiao. Yotiao binds with two regulatory subunits of protein kinase A (PKA) and protein 
phosphatase-1 (PP1) to form signaling complex which mediates phosphorylation of KCNQ1 
channel (Saucermann et al., 2004; Jespersen et al., 2005). The β-adrenergic stimulation 
increases intracellular cAMP levels leading to activation of PKA in the Yotiao and 
phosphorylation of N-terminal residue S27 in KCNQ1 α-subunit (Jespersen et al., 2005). 
Phosphorylated channel reacts on β-adrenergic stimulation by shortening action potential 
duration. But in the mutated KCNQ1 channels, phosphorylation does not occur because the 
mutation prevents α-subunits to interact with the Yotiao resulting in abnormal response for β-
adrenergic stimuli. Therefore, mutated KCNQ1 channels cannot increase repolarizing IKs 
current at the same rate than ICa current is increasing during β-adrenergic stimulation that lead 
to QT interval prolongation and development of cardiac symptoms (Saucermann et al., 2004). 
Additionally, there has been identified mutation in the KCNQ1 binding domain of Yotiao 
resulting in LQTS-related phenotype and it has determined to cause LQT11 subtype (Chen et 
al., 2007). The mutation in Yotiao affects similarly to KCNQ1 channel than KCNQ1-FinA 
mutation by reducing phosphorylation and channel’s response to increased cAMP levels.  
 
KCNQ1-FinB (IVS7-2A>G) is an acceptor site mutation which cause insertion of 30 or 33 
base pairs into the KCNQ1 gene by eliminating splicing site between exons 7 and 8 (Fodstad 
et al., 2006). The IVS7-2A>G-mutated transcripts are translated into KCNQ1 α-subunits 
containing inserted 10 (Val-Thr-Ala-Cys-Pro-Pro-Ala-Arg-Pro-Arg) or 11 (contain added 
glutamine in front of valine) amino acids from the end of intron 7 into the C-terminal part of 
the protein. Functional in vitro studies have revealed loss-of-function and dominant negative 
features of the KCNQ1-FinB resulting in reduction of IKs current in KCNQ1 channel and 
significantly prolonged QT interval in affected patients (Fodstad et al., 2006; Marjamaa et al., 
2009).  
 
HERG-FinA (L552S) mutation causes nucleotide change from thymine to cytosine at position 
1655 in the KCNH2 gene that leads to substitution of leucine by serine at position 552 in the 
HERG protein (Piippo et al., 2000; Splawski et al., 2000). The mutation locates in 
cytoplasmic end of S5 segment which is known to be important in regulation of deactivation 
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and inactivation of HERG channel (Piippo et al., 2000). Therefore, the HERG-FinA mutation 
affects especially gating properties of the channel. Piippo et al. (2000) found that the mutation 
reduces IKr current by increasing channel activation and deactivation rates. In addition, they 
identified Finnish homozygote HERG-FinA carriers with more severe disease phenotypes 
than heterozygote carriers have, as have been observed in JLNS cases caused by homozygous 
KCNQ1 and KCNE1 mutations. 
 
Laitinen et al. (2000) identified R176W mutation from KCNH2 gene but its founder mutation 
nature occurring in Finland was revealed by Fodstad et al. (2006) and it was named as HERG-
FinB. It is a missense mutation causing nucleotide change from cytosine to thymine in 
nucleotide 526 in KCNH2 gene (Laitinen et al., 2000) resulting in substitution of arginine by 
tryptophan in N-terminal part of the HERG subunit (Fodstad et al., 2006; Lahti et al., 2012). 
The HERG-FinB mutation increases deactivation rate of HERG channel due to nearby 
location with PAS (Per-Arnt-Sim) domain which is known to slow channel deactivation rate 
(Clancy and Rudy, 2001; Fodstad et al., 2006). When deactivation is accelerated the ability of 
the channel to conduct K
+
 ions is reducing that lead to prolonged repolarization of 
cardiomyocytes. One explaining factor for decreased IKr current is reduced trafficking of 
mutated α-subunits to the cell membrane resulting in lower amount of channel-forming α-
subunits in the membrane, because HERG-FinB mutated subunits are still able to interact with 
normal subunits and form tetrameric ion channels (Fodstad et al., 2006). However, Fodstad et 
al. (2006) suggested that HERG-FinB may have milder effect on disease phenotype than other 
LQTS-associated mutations because there was not detected significant difference between 
current densities of wild type α-subunits and coexpressed wild type and HERG-FinB mutated 
subunits. In addition, they observed that compound heterozygosity was relatively common 
among HERG-FinB mutation carriers, indicating that they have other LQTS-associated 
mutation along with HERG-FinB, and therefore, the HERG-FinB may increase the risk of 
occurrence of cardiac symptoms in these disease cases.  
 
Specific genetic spectrum has been related to LQTS-associated mutations in Finland, although 
LQTS-causing founder mutations have also been identified in Norway and South Africa 
(Fodstad et al., 2004). Geographical, linguistic, cultural and immigrational reasons have led to 
isolation of Finnish population during the history and that have enabled development and 
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enrichment of unique founder mutations (Piippo et al., 2000; Piippo et al., 2001; Fodstad et 
al., 2004). Founder mutations characterized from KCNQ1 gene have only been identified 
among Finnish population but HERG-related mutations have also been diagnosed within 
other populations (Marjamaa et al., 2009). Geographical distribution of founder mutations can 
reveal information about their development and origin (Kontula, 2005). There have been 
observed evident geographical clustering of birthplaces of ancestors affected by Finnish 
founder mutations (Piippo et al., 2001; Fodstad et al., 2004), but nowadays, any clustering 
within mutation carriers cannot be characterized (Marjamaa et al., 2009).  
2.3. Induced pluripotent stem cells 
Induced pluripotent stem cells (iPSC) are generated from somatic cells by returning them into 
pluripotent state by reprogramming (Takahashi and Yamanaka, 2006; Takahashi et al., 2007; 
Yu et al., 2007). Takahashi and Yamanaka (2006) developed the iPSC technology for intend 
to replace need of embryonic stem cells (ESCs) in research field by cells which have similar 
properties. They succeeded in producing pluripotent stem cells from mouse fibroblasts and 
later from human fibroblasts (Takahashi and Yamanaka, 2006; Takahashi et al., 2007). The 
reprogramming is occurred by viral transduction of somatic cells with a combination of four 
transcription factors, including either Oct4, Sox2, Klf4 and c-Myc (Takahashi et al., 2007) or 
Oct4, Sox2, Nanog and Lin28 (Yu et al., 2007), that are maintaining pluripotency within 
ESCs. During reprogramming, delivered exogenous transcription factors modify gene 
expression of somatic cells through remodeling epigenetic features of DNA that lead to 
activation of expression of endogenous pluripotency-associated genes while expression of 
genes associated with differentiation is suppressed (Takahashi et al., 2007). The exogenous 
transgene expression has silenced within generated iPSCs and active endogenous pluripotency 
genes maintain their returned properties related to pluripotent state.  
 
Many morphological and functional similarities between human iPSCs and human ESCs have 
been identified (Takahashi et al., 2007 ; Yu et al., 2007), such as similar colonies formed in in 
vitro cultures, equal self-renewal capacity and similar expression of pluripotency-related 
genes and surface markers. Both of them are able to differentiate into all cell types found in 
three germ layers: endoderm, mesoderm and ectoderm, and the differentiation capacity to 
create their derivatives are confirmed with in vitro formation of embryonic bodies (EB) and in 
vivo formation of teratomas (Lahti et al., 2012). However, isolation of ESCs from inner cell 
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mass of blastocyst causes ethical concerns considering the use of human embryos in 
researches (Takahashi and Yamanaka, 2006). In addition, ESCs are associated with a risk of 
immunological rejection. These problems can be avoided by using induced pluripotent stem 
cells instead. One great advantage of iPSCs is opportunity to generate patient- and disease-
specific cells that contain identical genome with individual whose somatic cells have been 
used for iPSC generation (Zwi et al., 2009).  
 
The iPSC-derived patient- and disease-specific cells have led to development of novel and 
efficient approach for disease modelling and drug development because previously only 
models used for studying human disease mechanisms were based on animals and 
heterologous expression systems which not reliable recapitulate disease phenotypes occurring 
in humans (Inoue and Yamanaka, 2011). Using iPSCs to model human diseases is based on 
ability to generate patient-specific pluripotent stem cells which contain specific disease-
causing gene mutations in natural genetic environment (Inoue and Yamanaka, 2011). Disease-
specific cells are produced from patient-specific stem cells by differentiating them into cell 
type affected in the disease allowing in vitro examination of disease mechanisms and 
phenotypic features. Especially iPSCs are great cell source for generating human cell types 
that are not otherwise available, and therefore many neurological and cardiological diseases 
have been modelled with iPSC-derived disease-specific cells (Inoue and Yamanaka, 2011).  
 
In addition to in vitro applications, clinical potential of iPSCs in the field of regenerative 
medicine for repairing tissue damages has been evaluated due to the possibility to produce 
genetically identical cells with a patient (Laflamme et al., 2007; Zwi et al., 2009; Yoshida and 
Yamanaka, 2011). However, several concerns have been related to their clinical use. Firstly, 
although many non-viral delivery methods for transducing exogenous reprogramming factors 
have been developed, their efficiencies do not reach reprogramming efficiencies of viral 
delivery methods (Zwi et al., 2009). Increased risk of tumorigenesis due to integrated viral 
genome into host cell genome and possible reactivation of exogenous oncogenic c-Myc have 
been associated with the use of viral transduction methods for generating iPSCs. Secondly, 
differentiation protocols produce commonly heterogeneous cell population containing 
variable maturities and phenotypic features (Zwi et al., 2009). Incomplete and variable 
differentiation is suggested to be caused by epigenetic memory, indicating that iPSCs contain 
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DNA methylation patterns related to their somatic cell origin (Kim et al., 2010). Thus, iPSCs 
differentiate rather into their original lineage than into other lineages. Integrated viral genome 
and expression of unsilenced transgene also affect differentiation capacities of iPSCs (Yu et 
al., 2007; Zhang et al., 2009). Thirdly, heterogeneity of iPSCs causes variable growth and 
differentiation potentials among the cell population and reduces similarities between iPSCs 
and ESCs, resulting in their limited clinical potential (Narsinh et al., 2011). Nevertheless, 
iPSCs provide a remarkable research tool for examining disease phenotypes and mechanisms, 
discovering and testing new therapeutics and evaluating their efficacies in disease treatments 
(Inoue and Yamanaka, 2011; Moretti et al., 2013).  
2.3.1. Cardiac differentiation of induced pluripotent stem cells 
To create reliable in vitro disease models, efficient and robust protocols for differentiating 
induced pluripotent stem cells into cell type of interest have to be existed. There are three 
main methods used for differentiating iPSCs into functional cardiomyocytes in in vitro 
conditions: embryonic body (EB) differentiation, monolayer culturing and inductive co-
culturing (Yoshida and Yamanaka, 2011; Mummery et al., 2012). The first attempts to 
generate cardiomyocytes from human iPSCs were performed by EB differentiation protocol 
that forms contracting embryonic bodies which express cardiac specific genes and proteins, 
have specific electrophysiological properties and react to β-adrenergic stimulation by 
increasing contraction rate (Zhang et al., 2009; Zwi et al., 2009). However, the amount of 
contracting EBs achieved by this differentiation protocol is not more than 10 % (Zhang et al., 
2009), indicating that efficiency to produce functional cardiomyocytes is relatively poor. For 
that reason, direct differentiation protocols were developed to generate iPSC-derived 
cardiomyocytes (Mummery et al., 2012). Monolayer culturing of iPSCs enables effective 
administration of growth factors, such as activin A and BMP4, required for generating 
functional cardiomyocytes, and permits that their effects are targeted directly at differentiable 
stem cells (Laflamme et al., 2007; Zhang et al., 2012). Therefore, cardiac differentiation in the 
monolayer cultures is significantly more effective than in the EBs and produced 
cardiomyocytes are related to higher purity than can be isolated from EBs (Zhang et al., 
2012). The other direct differentiation protocol is performed by co-culturing iPSCs with 
mouse visceral endoderm-like cells (END-2) which are able to induce differentiation of iPSCs 
into mesoderm-derived cardiac precursor cells, as known to occur during in vivo embryonic 
development (Mummery et al., 2003; Pekkanen-Mattila et al., 2009). This inductive co-
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culture protocol is generally used to confirm cardiac differentiation capacity of iPSCs because 
it allows rapid production of functional cardiomyocytes (Mummery et al., 2012).  
 
The in vitro cardiac differentiation of iPSCs mimics naturally occurring embryonic 
development of the human heart, known as cardiogenesis (Mummery et al., 2012). The 
differentiation process contains multiple steps that are regulated by various signaling 
pathways and growth factors (Moretti et al., 2013) which are represented in details in the 
figure 4. Bone morphogenetic proteins (BMPs), wingless/INT proteins (WNTs), fibroblast 
growth factors (FGFs), transforming growth factor β1 (TGF-β1) and activin A are major 
factors to regulate signaling pathways during cardiac development resulting in generation of 
multipotent cardiovascular progenitor cells having capacity to differentiate into 
cardiomyocytes, smooth muscle cells and vascular endothelial cells (Takahashi et al., 2007; 
Mummery et al., 2012; Moretti et al., 2013). During in vitro cardiac differentiation of iPSCs, 
sequential and accurate administration of growth factors by following their naturally 
occurring order allows efficient cardiomyocyte generation. Administration of activin A 
induces development of mesodermal progenitors which further differentiate into functional 
cardiomyocytes by adding BMP4 and bFGF (Zhang et al., 2012). Developmental stages 
within cardiac differentiation are characterized by immunocytochemical staining specific 
markers expressed by cells in different stages (figure 4.) (Mummery et al., 2012; Moretti et 
al., 2013).  
 
In addition that cardiomyocytes are characterized by immunostaining cardiac structural 
proteins described in figure 4., their functionality has to be evaluated. Functional 
cardiomyocytes are able to contract spontaneously that can be observed as beating clusters in 
cell cultures. Their electrophysiological properties are detected and measured by using 
multielectrode array (MEA) (Zwi et al., 2009) or patch-clamp technology (Mummery et al., 
2012). MEA is used for analyzing multicellular electrical activity (Egashira et al., 2012; 
Mummery et al., 2012) and contraction capacity (Zhang et al., 2009) from a beating cell 
cluster formed by cardiomyocytes by measuring field potential duration that can be used for 
calculating duration of QT interval (Matsa et al., 2011). Action potential development and 
duration can be evaluated with patch-clamp technology by determining ion conductance of
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Figure 4. Cardiac differentiation of human induced pluripotent stem cells. Signaling pathways 
and growth factors (represented with blue) involve in progression of cardiac differentiation by 
either activating or inhibiting it. Specific markers expressed by cells in different 
developmental stages are described below the cell figures. Those could be used for 
characterizing distinct cells within developmental stages by immunocytochemical staining. 
The figure was modified from the origin Moretti et al., 2013. 
 
cardiac ion channels within a single cardiomyocyte (Matsa et al., 2011; Mummery et al., 
2012). Therefore, it is extremely useful for studying arrhythmic mechanisms caused by ion 
channel mutations or pharmaceuticals. Moreover, isoproterenol treatment is used to evaluate 
response of cardiomyocytes to β-adrenergic stimulation. Isoproterenol is an agonist for β-
adrenoreceptor (Matsa et al., 2011) and therefore its administration into cardiomyocytes 
accelerates contraction rate and shortens APD (Zhang et al., 2009; Zwi et al., 2009). In 
LQTS-specific cardiomyocytes, isoproterenol commonly induces development of arrhythmic 
events and EADs (Egashira et al., 2012) and that is why it is generally used for reproducing 
arrhythmias, particularly TdPs, occurring in LQTS. 
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2.3.1.1. Modelling of long QT syndrome with disease-specific iPSCs 
Human long QT syndrome has been attempted to recapitulate in many mouse models, but 
significant differences in electrophysiological properties between humans and mice have led 
to unsuccessful disease modeling. Although many similarities in ion channel structures have 
been detected, mice have 10-times faster heart rate than humans have, resulting in differences 
in ECGs and action potentials between the species (Salama and London, 2007). Furthermore, 
recapitulating human arrhythmic phenotypes of LQT1 and LQT2 subtypes by mouse models 
has emerged to be remarkably challenging due to the functional differences in cardiac K
+
 ion 
channels (Salama and London, 2007). In contrast, zebra fish model for human LQT2 
succeeded to recapitulate specific disease phenotype, including prolonged APD and QT 
interval and reduced IKr current in HERG channels (Arnaout et al., 2007). In addition, many 
heterologous expression systems have been used to study disease mechanisms of LQTS, but 
the lack of appropriate cardiac environment and channel-associating molecules have 
hampered reproduction of disease phenotypes (Medeiros-Domingo et al., 2007).  
 
Several long QT syndrome models derived from disease-specific iPSCs have successfully 
reproduced specific LQTS-related disease phenotypes. Human LQTS models for LQT1 
(Moretti et al., 2010; Egashira et al., 2012) and LQT2 (Itzhaki et al., 2011; Matsa et al., 2011; 
Lahti et al., 2012) subtypes have been characterized with typical electrophysiological features, 
such as prolonged APD caused by delayed repolarization phase and decreased amplitudes of 
K
+
 ion currents, within iPSC-derived cardiomyocytes. Most of LQTS-specific cardiomyocytes 
used for disease modelling have been generated from patients who have experienced cardiac 
events during their lifetime (Itzhaki et al., 2011; Matsa et al., 2011; Egashira et al., 2012), but 
Lahti et al. (2012) succeeded to recapitulate LQT2-related disease phenotype from 
cardiomyocytes generated from asymptomatic patient with diagnosed HERG-FinB mutation, 
one of the four Finnish founder mutations. These findings indicate that LQTS models with 
specific phenotypic features can be generated from iPSC-derived cardiomyocytes of patient 
without manifested cardiac events (Lahti et al., 2012). Such disease models can be used to 
investigate cellular mechanisms that affect development of cardiac events among LQTS 
patients by comparing them with disease models generated from symptomatic mutation 
carriers. Long QT syndrome is an ideal disease to be modelled with iPSC-derived 
cardiomyocytes due to that underlying genetic cause and specific phenotypic features are 
mostly solved (Moretti et al., 2013). Thus, these LQTS disease models offer a tool for 
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studying more specific, relatively unknown, features. For example, they permit investigation 
of genetic and non-genetic factors that may cause phenotypic variation within LQTS patients 
(Lahti et al., 2012). However, current cardiac differentiation protocols commonly generate 
heterogeneous and poorly maturated cardiomyocyte population with phenotypic 
characteristics for all atrial, ventricular and nodal cells leading to reduced reliability of their 
usage for cardiac disease modelling (Zhang et al., 2012; Moretti et al., 2013).  
 
In vitro LQTS disease models are perfect platforms to test and discover novel 
pharmaceuticals. Nowadays, main reasons for failed preclinical and clinical studies during 
drug development are cardiotoxicity, hepatotoxicity or neurotoxicity of tested medicines due 
to that these toxic effects can remain to be undetected in animal model studies performed 
during drug testing, and therefore risk of severe side effects is increasing (Inoue and 
Yamanaka, 2011). LQTS disease models can be utilized for predicting possible cardiotoxic 
effects. In addition, drug efficiency and required drug dosage to improve disease phenotypic 
features, such as shortening APD or preventing development of EADs, can be evaluated from 
LQTS models (Itzhaki et al., 2011). Due to the drug-induced form of LQTS caused by 
inhibited function of HERG ion channels, it is significantly important to identify drugs which 
have QT interval prolonging effects and may cause arrhythmic events (Itzhaki et al., 2011; 
Matsa et al., 2011; Egashira et al., 2012; Lahti et al., 2012). For their identification, LQTS 
models provide a useful detection system due to that their arrhythmogenic susceptibilities are 
already high. 
2.4. Cell characterization with quantitative real-time PCR 
Quantitative real-time PCR (qPCR) enables amplification of target gene by polymerase chain 
reaction (PCR) simultaneously with detection and quantification of amplifying PCR products 
(Heid et al., 1996; Arya et al., 2005). By using qPCR, pieces of genomic DNA can be 
detected using specific markers that allow evaluating of gene expression of interest. Thus, it is 
extremely useful method for cell and cell line characterization. Accurate and appropriate 
quantification is based on carefully designed primers and probes which permit amplification 
and detection of desired gene target, respectively. The qPCR system contains sequence 
detector which measures continuously fluorescent emissions occurring during PCR 
amplification (Heid et al., 1996). The detectable fluorescent emissions are resulted from 
fluorescent probes which have bound with amplifying targets. Mostly probes are labelled with 
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fluorescent dyes that develop fluorescence signals when cleaved from probe fragments (Heid 
et al., 1996). In addition, detection systems based on DNA-binding dyes, such as SYBR® 
Green 1, are used to quantify target expression during PCR amplification (Arya et al., 2005). 
DNA-binding dyes bind with all double-stranded DNA that is present in PCR reaction leading 
to increased risk of nonspecific detection. In contrast, fluorescent probes hybridize 
complementary with target sequence that increases specificity and reliability of detection of 
amplifying targets (Arya et al., 2005). Detection mechanisms of fluorescent probes are 
discussed in details in the next section, concentrating on chemistry of TaqMan® fluorescent 
probes. 
 
Few parameters are essential to be familiar when PCR amplification data is analyzed. The 
amplification plot contains threshold level that is chosen according to baseline level, meaning 
the level in which detection capacity of qPCR system to observe fluorescence signals initiates 
(Arya et al., 2005). The threshold cycle or Ct value indicates the PCR cycle number in which 
fluorescence signal becomes distinguishable from the background fluorescence, and therefore, 
it describes the cycle number initiating detection of target during qPCR analysis. Ct values are 
directly comparative with initial target template concentrations (Heid et al., 1996; Arya et al., 
2005). High initial concentration of target results in lower Ct values due to that there is higher 
amount of templates to be bound by probes, leading to earlier development and detection of 
fluorescence signals.  
 
There are two main methods to evaluate qPCR results: standard curve and relative 
quantification (Livak et al., 2001; Arya et al., 2005). Standard curve method is based on 
generated standard samples containing known DNA concentrations by serially diluting them 
(Arya et al., 2005). Therefore, standard curve can be used for determining DNA 
concentrations of unknown samples by using their qPCR-measured Ct values. The other 
method is a relative quantification that enables quantification of target gene expression by 
normalizing the expression with endogenous housekeeping gene’s expression (Livak et al., 
2001; Arya et al., 2005). The used equation in that method is 2
-ΔΔCt, where ΔΔCt = ΔCt 
(sample) - ΔCt (control), and ΔCt = Ct (target gene) - Ct (housekeeping gene) (Livak et al., 
2001). Appropriate housekeeping gene, which can be selected for normalization, has equal 
PCR amplification efficiency than target gene has and has constant expression levels in 
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different tissues (Arya et al., 2005). Selection of quantification method is dependent on the 
way that target gene expression is desired to be determine. The standard curve method 
permits absolute gene expression determinations; whereas the 2
-ΔΔCt
 method is more useful if 
target gene expression is determined as fold changes by comparing with expression of control 
gene (Livak et al., 2001).  
2.4.1. TaqMan® Assays 
TaqMan® Assays used in qPCR analysis provide allele-specific detection and quantification 
of amplified DNA samples. The main function of TaqMan® Assay during PCR reaction is 
represented in the figure 5. They contain forward and reverse primers which initiate 
amplification of target sequence resulted in polymerization of new complementary DNA 
strands. In addition, TaqMan® Assays contain specific probes designed to bind with specific 
genomic site of target sequence between primer binding sites and they are responsible for 
detection of amplifying target by qPCR system. Probe’s 5’-end is labelled with reporter dye 
or fluorophore which function is prevented by 3’-end labelled quencher dye before PCR 
reaction (Arya et al., 2005). According to manufacturer’s protocol for TaqMan® Universal 
PCR Master Mix (Applied Biosystems, Life Technologies Ltd.), AmpliTaq Gold® DNA 
polymerase performs polymerization of target sequence initiating from primers. The enzyme 
has 5’-3’ nuclease activity causing degradation of bound probe when polymerizing strand 
reaches the probe. Therefore, fluorophore releases from the probe and it is not any longer be 
prevented by quencher dye, leading to occurrence of fluorescence signal. The qPCR system 
detects and measures fluorescence signal intensities that are increasing simultaneously when 
the amounts of amplified PCR products are increasing (Arya et al., 2005), and forms an 
amplification plot for each analyzed DNA sample according to its increased fluorescence 
intensity during PCR cycles.  
 
TaqMan® Assays enable detection of allelic expression differences within heterozygous 
DNA samples. For example, they can be used for detecting expression differences between 
wild type and mutant alleles of certain gene. In order to examine allelic expression 
differences, TaqMan® Assays containing two different probes labelled with different 
fluorophores are used. Therefore, they generate different fluorescence signals during PCR 
reaction permitting detection of distinct allelic expressions. The probes are designed to 
hybridize with genomic sites where single nucleotide polymorphism (SNP) or mutation
26 
 
Figure 5. Function of TaqMan® Assays during PCR reaction. AmpliTaq Gold® DNA 
polymerase initiates polymerization of complementary DNA strand for target sequence from 
bound primers. Progressing polymerization displaces hybridized probe causing release of 
fluorophore and occurrence of fluorescence signal that is detected by qPCR system. 
 
locates in mutant allele and corresponding site of the wild type allele. The qPCR system 
creates an allelic discrimination plot according to the measured fluorescence signal intensities 
from both probes that are described separately by y-axis and x-axis. If the qPCR system 
detects only one fluorescence signal, the DNA sample contains homozygote alleles, indicating 
either two wild type alleles or two mutant alleles depending on detected fluorophore signal. 
But if it measures fluorescence signals from both fluorophores, the DNA sample is 
heterozygous and contains both alleles. The proportions of detected fluorescence signals are 
described on the allelic discrimination plot allowing investigation of allelic expression 
differences within heterozygote sample. 
2.4.2. Determination of allelic expression variation with quantitative real-
time PCR 
Variation in allelic expression is common among human genes between individuals and 
therefore it may be a genetic factor promoting disease development and causing phenotypic 
variation among humans (Lo et al., 2003; Buckland, 2004). Several familiar gene expression 
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variations occur in human genomes, such as X chromosome inactivation and identified 
imprinted genes that lead to expression of only one allele (Lo et al., 2003), and thereby may 
cause variation among mutation carriers with differently expressed alleles (Saenen and Vrints, 
2008). In addition, many other human genes have shown differences in allelic expression that 
are suggested to be caused by gene transcription regulation, such as cis-acting elements or 
epigenetic modifications (Buckland, 2004), resulting in higher expression levels of other 
allele. Especially, variations in promoter regions or non-coding regions alter transcription 
rates due to defective binding of transcription factors or transcription regulation leading to 
variable expressions of alleles (Chen et al., 2008; Shen et al., 2011). However, many 
regulatory regions are mostly unidentified that have complicated determination of allelic 
imbalance effects for phenotypic features. Many methods for study variable allele-specific 
expression and quantify mRNA levels transcribed from both alleles have been developed, 
such as allele-specific microarray and single nucleotide primer extension (Buckland, 2004).  
 
There are two main procedures to determine allelic expression differences of certain gene by 
using standard curves. The first one uses homozygote genomic DNA (Lo et al., 2003) or 
cDNA (Chen et al., 2008; Shen et al., 2011) derived from two individuals to produce standard 
samples, whereas the second method generates plasmids containing wild type and mutant 
inserts which are mixed with appropriate ratios (Moretti et al., 2010). Chen et al. (2008) 
examined the influences of allelic imbalances of BRCA1 and BRCA2 genes for breast cancer 
development. Allele-specific expression analysis was performed by using cDNA ratios 
generated from homozygous lymphocytes with specific polymorphisms in BRCA1 (BRCA1-
c.4308T/T or BRCA1-c.4308C/C) or BRCA2 (BRCA2-c.3396A/A or BRCA2-c.3396G/G) 
genes. The homozygote cDNA samples were mixed together with various ratios: 8:1, 4:1, 2:1, 
1:1, 1:2, 1:4 and 1:8 in order to form allelic expression standard curves for BRCA1 and 
BRCA2. Those standard curves were used to determine allelic imbalance of either BRCA1-
c.4308T/C or BRCA2-c.3396A/G heterozygote cells. They noticed that allelic imbalance of 
those genes is associated with increased risk of breast cancer. The mRNA and protein 
expression levels can reduce as a result of allelic expression differences and that could lead to 
development of disease state (Chen et al., 2008). Shen et al. (2011) used the same method to 
evaluate the effects of allelic imbalance related to BRCA1 and BRCA2 genes for development 
of familial ovarian cancer. They confirmed that high allelic imbalance of BRCA1 gene is 
significantly related to low mRNA expression levels and increased risk of familial ovarian 
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cancer. Therefore, allelic imbalance might be remarkable genetic factor to contribute disease 
development and phenotypic variations. 
 
Plasmid-derived standard curve method for determining allelic imbalance was developed by 
Moretti et al. (2010). They generated two plasmids: one contained insert of genomic site of 
wild type allele and the other contained insert of corresponding mutant allele with specific 
LQT1-causing KCNQ1 gene mutation. R190Q is a missense mutation locating in cytoplasmic 
loop between S2 and S3 segments of KCNQ1 α-subunit (Moretti et al., 2010). The mutational 
mechanism related to it is reduced transportation of mutated α-subunits to the cell membrane 
leading to decreased amount of functional IKs-conducting K
+
 ion channels in dominantly 
negative manner. Wild type and mutant plasmids were mixed with similar ratios described by 
Chen et al. (2008) and standard curve was plotted log2(WT/MUT) vs. ΔCt values. Allelic 
expression differences of heterozygote patient-specific iPSC-derived cardiomyocytes were 
analyzed from standard curve. They observed that R190Q-mutated cardiomyocytes had equal 
expression of wild type and mutant alleles, and any mRNA or protein level differences were 
not detected between LQT1-specific and control cardiomyocytes. 
2.4.3. Single-cell gene expression analysis by using quantitative real-
time PCR 
Interest toward single-cell technologies has increased during few decades in research field 
because they enable to examine and evaluate behavioral and functional differences between 
single cells within cell population (Kalisky et al., 2011). Those technologies identify 
heterogeneity by detecting and quantifying mRNA transcripts of target genes with fluorescent 
in situ hybridization, qPCR or microarray methods or ultimately sequencing whole genome in 
order to access genetic information cannot be examine with other methods (Kalisky et al., 
2011; Ståhlberg et al., 2011). Functional cell-to-cell variations cannot be determined with cell 
population studies due to that individual cells have their own gene expression profile causing 
differences in mRNA and protein levels that affect to development of different cell fates 
(Peixoto et al., 2004; Bengtsson et al., 2008). It has also been observed that gene expression 
levels may differ significantly between studies performed at cell population or single cell 
levels, leading to suggestions that gene expression occurring in cell population is average of 
the expression occurring within individual cells (Peixoto et al., 2004; Fox et al., 2012). 
Cellular mechanisms that cause gene expression variation and heterogeneity among even 
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genetically and phenotypically identical cell population are highly unidentified (Glotzbach et 
al., 2011). Stochastic gene expression has been suggested to be a potential mechanism leading 
to variable expressions and transcription rates between individual cells (Elowitz et al., 2002; 
Raj et al., 2010). In addition, available transcriptionally active chromatin causes gene 
expression differences and it could be promoted by mutations in molecules regulating 
chromatin’s conformational changes (Raj et al., 2010).  
 
Because mRNA levels in individual cells are very low, multiple gene expression analysis has 
to perform in a single PCR reaction containing multiple primers for amplifying all target 
genes of interest (Taniguchi et al., 2009). Therefore, any competition between used primers at 
pre-amplification or amplification stages may induce unbalanced amplification of targets 
causing higher amplification of particular target mRNAs, while the other mRNAs are not 
amplified with the same rate and efficiency (Peixoto et al., 2004). Thus, possible primer 
competition has to be evaluated before qPCR analysis in order to achieve efficient and 
accurate single-cell multiplex gene expression analysis. To evaluate primer competition, pre-
amplification is performed separately with single and pooled primers, and if these 
experiments produce similar Ct values during qPCR analyses, primers are not competitive 
(Ciriza et al., 2012). But if any competition is observed, gene expression analyses have to 
perform separately with divided single cell samples or other methods have to be used 
(Taniguchi et al., 2009). Pre-amplification is usually necessary to perform before qPCR 
analysis in order to increase the amount of target template and it can be performed by either 
selective amplifying specific mRNA targets or amplifying all mRNAs present in cells 
(Freeman et al., 1999). Additionally, it has been observed that current single-cell gene 
expression technologies determine effective gene expression from abundant mRNAs but their 
efficiencies are not sufficient to quantify expression of more rare mRNAs (Bengtsson et al., 
2008).  
 
Before quantification of gene expression levels, single cells are isolated from heterogeneous 
population by using appropriate techniques. Single cells can be collected by manually 
isolating cells of interest with micropipette (Freeman et al., 1999), or using more technical 
methods, such as laser capture microdissection (Fox et al., 2012) or fluorescence activated 
cell sorting (Glotzbach et al., 2011; Narsinh et al., 2011). Single cell isolation is usually 
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followed by cell lysis in many technologies (Fox et al., 2012) due to that using cell lysis can 
be avoided loss of mRNAs associated with basic RNA purification methods (Bengtsson et al., 
2008). Techniques developed for characterizing single-cell gene expression are commonly 
based on the use of basic qPCR or microfluidic PCR (Fox et al., 2012). When comparing to 
basic qPCR analysis, the significant advantage of microfluidic PCR analysis is the capacity to 
perform thousands of single cell assays parallel in tiny reaction volumes (White et al., 2011) 
and therefore, it enables single-cell gene expression analysis in high throughput manner. 
Chip-based (Glotzbach et al., 2011; White et al., 2011) and droplet-based (Brouzes et al., 
2009) approaches are used in microfluidic PCR analysis. Both methods permit gene 
expression analysis in integrated and automatic processes, indicating that total workflow 
initiating from single cell isolation and finishing to detection of target gene expression is 
performed sequentially and simultaneously in the same device. 
 
Single-cell gene expression analysis permits characterization of single cells among population 
based on their specific gene expression profiles that could be earlier studied only at cell 
population level (Peixoto et al., 2004; Narsinh et al., 2011). Multiple population heterogeneity 
determinations have been performed by using qPCR-based methods. For example, significant 
gene expression heterogeneity has been revealed to occur within induced pluripotent stem 
cells and iPSC-derived differentiated cell types that affect their pluripotencies and 
differentiation capacities (Narsinh et al., 2011). The population heterogeneity studies may 
provide essential new knowledge about functional roles of individual cells in development or 
progression of disease state (Fox et al., 2012). Single-cell based analysis has been used in 
clinical diagnostic tests, especially in cancer (Ståhlberg et al., 2011) and stem cell (White et 
al., 2011) researches due to that heterogeneity within these cell populations are commonly 
high. In tumor diagnostics, the single-cell gene expression analysis permits characterization of 
specific cell types, such as cancer stem cells and circulating tumor cells, within tumor cell 
population and therefore facilitates their identification and enhances the treatment decisions 
(Ståhlberg et al., 2011). However, efficiencies of many gene expression analysis technologies 
are nowadays still limited to characterize cells on the cell population level, although the 
development of single-cell based technologies has increased enormously.  
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3. Aim of study 
The aim of this study was to evaluate specific genetic features occurring within LQTS-
specific cardiomyocytes by using quantitative real-time polymerase chain reaction. This study 
consisted of three different experiments in which qPCR was used to detect either 
amplification of cardiac ion channel genes or typical structural genes or their allelic 
expression differences in order to characterize iPSC-derived LQTS-specific cardiomyocytes 
contained predominating disease-causing mutations in Finland.  
 
In the first experiment was evaluated capacity of cell lysis -based genotyping method to 
characterize cardiac cell lines with appropriate detection specificity. The purpose was to solve 
if the method could be used for facilitated genotyping of disease-specific cardiac cell lines in 
an everyday routine manner. In the second experiment, the effect of allelic expression 
variation for variable phenotypic features associated with LQTS was evaluated by using 
plasmid-derived standard curve method and qPCR (Moretti et al., 2010). Allelic imbalance 
determinations were performed for Finnish founder mutation specific cardiomyocytes and 
therefore the study was also allowed investigations of genetic mechanisms which may have 
enhanced enrichment of those mutations among Finnish population and lead to development 
of milder phenotypic effects suggested to be related to founder mutations (Piippo et al., 2001).  
 
The intend of the final experiment was to led cardiomyocyte characterization from cell 
population level to the single cell level by using specific qPCR-based procedure for 
evaluating expressions of basic structural protein within low amount cell samples and 
multiple cell samples. Single-cell gene expression analysis methods enable to examine cell 
population heterogeneity causing variations for functions and behaviors of individual cells 
(Kalisky et al., 2011). Therefore, this single-cell qPCR analysis was expected to reveal 
whether the method could be able to characterize more specific cardiac gene expressions in 
the future.  
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4. Materials and methods 
4.1. Disease-specific induced pluripotent stem cells 
Disease-specific iPSCs were generated from fibroblasts isolated from skin biopsies of patients 
who carry LQTS-related Finnish founder mutations (KCNQ1-FinA, KCNQ1-FinB, HERG-
FinA or HERG-FinB). Isolation and use of patient-specific cells in researches were approved 
by the ethical committee of Pirkanmaa Hospital District (R07080). Fibroblast culturing 
conditions in which isolated fibroblasts were maintained have been described previously by 
Lahti et al. (2012).  
 
Reprogramming of patient-specific fibroblasts was performed with iPSC technology 
developed by Takahashi et al. (2007). Four transcription factors, Oct4, Sox2, Klf4 and c-Myc, 
were delivered into fibroblasts using first lentiviral vectors followed by transduction with 
retro- or Sendai-viruses (Lahti et al., 2012). The plasmids, cells and reagents used in 
reprogramming processes have been represented previously (Lahti et al., 2012). In this study, 
six LQTS-specific iPSCs lines and three iPSCs lines derived from healthy individuals have 
been used (table 2.). Their pluripotency were confirmed by immunocytochemical staining the 
protein expressions of pluripotency-related genes, and their differentiation capacity to form 
EBs in vitro and teratomas in vivo which contain derivatives from all three germ layers was 
verified as has been described by Lahti et al. (2012).  
4.1.1. Cardiac differentiation of iPSCs 
Cardiac differentiation of patient-specific iPSCs was performed by co-culturing them with 
END-2 cells, as has been described previously (Mummery et al., 2003; Pekkanen-Mattila et 
al., 2009). Co-culture with END-2 cells induced differentiation of iPSCs into cardiomyocytes 
which formed beating clusters in the cell culture plates. Their differentiation was verified by 
immunocytochemical staining the protein expressions of cardiac specific genes and detecting 
specific electrophysiological features (Lahti et al., 2012). LQTS-specific cardiac cell lines and 
wild type cell lines that were used in this study are represented in the table 2. 
4.2. RNA isolation and cDNA transcription 
Beating areas containing functional cardiomyocytes were cut by using scalpel under a 
microscope and the areas were transferred into Lysis Buffer R1 with β-mercaptoethanol for 
RNA isolation. In this study, NucleoSpin® RNA II Kit (Macherey-Nagel GmbH & Co.,
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Table 2. iPSC-derived cardiac cell lines used in this study. Letter “s” in the end of names 
UTA.04311.WTs and UTA.04511.WTs indicates that those cardiomyocyte lines have been 
differentiated from iPSC lines transduced by Sendai-virus. Otherwise, retroviral transduction 
for reprogramming has been used.  
Cardiac cell line Disease Mutation 
UTA.00208.LQT1 Long QT syndrome type 1 KCNQ1-FinA (G589D) 
UTA.02201.LQT1 Long QT syndrome type 1 KCNQ1-FinA (G589D) 
UTA.00118.LQT1 Long QT syndrome type 1 KCNQ1-FinB (IVS7-2A>G) 
UTA.03412.LQT2 Long QT syndrome type 2 HERG-FinA (L552S) 
UTA.03810.LQT2 Long QT syndrome type 2 HERG-FinA (L552S) 
UTA.00525.LQT2 Long QT syndrome type 2 HERG-FinB (R176W) 
UTA.04602.WT None None 
UTA.04311.WTs None None 
UTA.04511.WTs None None 
 
Düren, Germany) was used for total RNA isolations by following purification protocol 
described by manufacturer. The concentrations of isolated RNA samples were measured with 
NanoDrop 1000 spectrophotometer (Thermo Scientific, Wilmington, DE, USA). Then, 
isolated RNAs were reverse transcribed to complementary DNAs (cDNA) by using High 
Capacity cDNA Reverse Transcription Kit (Applied Biosystems, Life Technologies Ltd., 
Carlsbad, CA, USA). The cDNA transcription was occurred according to manufacturer’s 
protocol, and used reverse transcription master mix contained 2 µl 10x RT Buffer (1.0 ml), 
0,8 µl 25x dNTP Mix (100 mM), 2µl 10x RT Random Primers (1,0 ml), 1µl MultiScribe™ 
Reverse Transcriptase (50 U/µl), 0,5 µl RNase Inhibitor (100 µl) and 3,7 µl DNase-free 
water. For every cDNA transcription, 10 µl RNA was added into 10 µl reverse transcription 
master mix. Thermal cycler used for cDNA transcription was Eppendorf MasterCycler EP 
Gradient S (Eppendorf, Hamburg, Germany) and used RT-PCR program was 10 min 25°C, 
120 min 37°C and 5 min 85°C. 
4.3. Cell line characterization 
Commercially available TaqMan® Sample-to-SNP™ Kit (Applied Biosystems, Life 
Technologies Ltd., Carlsbad, CA, USA) was used for performing cell line characterization of 
UTA.00208.LQT1 (heterozygous for KCNQ1-FinA mutation), UTA.04311.WTs and 
UTA.04511.WTs cell lines. Characterized cell samples were made by scratching the bottom 
of the cell culture plate with pipette’s tip and transferring detached cells into the tubes 
containing culture media. Cell samples were lysed according to the protocol’s instruction for 
cell culture suspension. PCR reaction master mix contained 10 µl 2x TaqMan® GTXpress 
Master Mix, 0,5 µl 40x Custom TaqMan® SNP Genotyping Assay and 5,5 µl DNase-free 
water. Used Custom TaqMan® SNP Genotyping Assay (Applied Biosystems, Life 
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Technologies Ltd., Carlsbad, CA, USA) contained primers and probes which were designed 
to amplify and detect KCNQ1-FinA mutated alleles and corresponding wild type (WT) alleles 
from cardiomyocyte samples. The Custom TaqMan® SNP Genotyping Assay was obtained 
from Assay service (Life Technologies Ltd.) and its assay ID and sequences of primers and 
probes are represented in the table 4. PCR reaction volume was 20 µl consisted of 16 µl PCR 
reaction master mix and 4 µl cell lysate. Each cell sample was analyzed as triplicates. The 
qPCR analysis was performed with 7300 Real-Time PCR System (Applied Biosystems, Life 
Technologies Ltd.) and thermal cycler condition at amplification phase was 2 min at 50°C, 10 
min at 95°C, and 40 cycles of 15 sec at 95°C and 1 min at 60°C. Before amplification, pre-run 
was performed to measure background fluorescence, and after amplification, post-run was 
performed to determine fluorescence signal intensities from plate wells contained analyzed 
cardiomyocyte samples. The 7300 System SDS software (version 1.4) created allelic 
discrimination plot according to measured fluorescence intensities that were stored into the 
PCR amplification data.  
4.4. Generation of plasmids for allelic imbalance determination 
To determine allelic imbalances of KCNQ1-FinA, KCNQ1-FinB, HERG-FinA and HERG-
FinB mutations, wild type (WT) and mutant (MUT) plasmids were generated by inserting 
corresponding fragments of wild type allele and mutant allele of each mutation. WT plasmids 
were generated from cDNA sample of UTA.04602.WT cell line by amplifying genetic site of 
wild type alleles with specific primers designed for each mutation. Forward primers and 
reverse primers (table 3.) had restriction sites for BamHI (Thermo Fisher Scientific Inc., 
Waltham, MA, USA) and NotI (Thermo Fisher Scientific Inc.) enzymes, respectively. The 
sizes of the wild type inserts were 382 bp, 482 bp, 320 bp and 233 bp for KCNQ1-FinA, 
KCNQ1-FinB, HERG-FinA and HERG-FinB mutations, respectively. Wild type and mutant 
allele fragments were inserted into pBluescript SK+ plasmids (Addgene, Cambridge, MA, 
USA) which have also restriction sites for BamHI and NotI, and therefore proper ligations of 
amplified wild type and mutant alleles into plasmids were occurred. 
 
Mutant plasmids for KCNQ1-FinA and KCNQ1-FinB were produced from heterozygous 
cDNA samples of UTA.00208.LQT1 and UTA.00118.LQT1 cell lines, respectively, by 
amplifying mutant alleles with specific primers (table 3.) in PCR reactions. After PCR 
amplification, heterozygous amplified cDNAs of KCNQ1-FinA and KCNQ1-FinB specific 
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cardiomyocytes were treated with KasI restriction enzyme (New England Biolabs, Ipswich, 
MA, USA) in order to digest WT alleles and remain mutated alleles. Mutant inserts were 
purified using agarose gel electrophoresis before their insertions into BamHI-NotI-site of 
pBluescript SK+ plasmids (Addgene). The mutant insert contained KCNQ1-FinA mutation 
was 382 bp long, and the mutant insert contained KCNQ1-FinB mutation was 512 bp long, 
indicating insertion of 30 bp as compared to wild type insert (482 bp). Mutant plasmids of 
HERG-FinA and HERG-FinB were generated from their WT plasmids by using QuikChange 
II Site-Directed Mutagenesis Kit (Agilent Technologies Inc., Santa Clara, CA, USA). 
Designed mutagenic primers containing desired KCNH2 mutations are described in the table 
3. Mutagenesis of WT plasmids were induced according to manufacturer’s instructions. All 
plasmid constructs were sequenced for verifying proper insertion of wild type and mutant 
fragments.  
Table 3. The sequences of primers used in PCR amplification and QuikChange II Site-
Directed Mutagenesis during plasmid generation for allelic imbalance determination. Forward 
and reverse primers contained BamHI and NotI restriction sites, respectively. Mutagenic 
primers were used only for HERG plasmids to produce specific mutations (HERG-FinA or 
HERG-FinB) into wild type plasmids.  
Target PCR amplification: 
forward primer with 
BamHI restriction site 
(5’-3’) 
PCR amplification: 
reverse primer with 
NotI restriction site 
(5’-3’) 
Mutagenesis:  
sense primer  
(5’-3’) 
Mutagenesis: 
antisense primer  
(5’-3’) 
KCNQ1-
FinA 
GCGGGATCCGAAA
TTCCAGCAAGCGC
GGA 
GCCGCGGCCGCCA
GGAAGAGCTCAGG
GTCGA 
  
KCNQ1-
FinB 
GCGGGATCCTTTG
CCATCTCCTTCTTT
GC 
GCGGCGGCCGCGT
CTCCCCTTCCAGGT
CC 
  
HERG-
FinA 
GCGGGATCCCTGA
AGACTGCGCGGCT
GCT 
GCGGCGGCCGCGG
CCGACACGTTGCC
GAAGA 
GCGGCCGTGCTGT
TCTCGCTCATGTGC
A 
TGCACATGAGCGA
GAACAGCACGGCC
GC 
HERG-
FinB 
GCGGGATCCGGCT
CATGACACCAACC
ACCGG 
GCGGCGGCCGCCC
ATGGCTGTCACTT
CGTCCAG 
CGCTGACGGCCTG
GGAGTCGTCG 
CGACGACTCCCAG
GCCGTCAGCG 
 
Generated WT and MUT plasmids were transferred to H7 bacteria cells to grow and multiply 
over a night at 37 °C. The plasmids were purified from bacteria cell cultures by using 
NucleoBond® Xtra Midi (Macherey-Nagel GmbH & Co., Düren, Germany) method and 
purifications were performed by slightly modifying manufacturer’s protocol. Structural 
integrities of purified plasmids were confirmed by running samples on 1% agarose gel. 
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Plasmid purities and DNA concentrations were measured with NanoDrop 1000 
spectrophotometer (Thermo Scientific).  
4.5. Allelic imbalance determination 
Allelic imbalance determinations were performed for KCNQ1-FinA, KCNQ1-FinB, HERG-
FinA and HERG-FinB mutations by utilizing the capacity of qPCR to detect allelic expression 
differences between wild type and mutant alleles of heterozygous disease-specific 
cardiomyocytes. Allelic imbalances were determined by plasmid-derived standard curve 
method that has been described previously by Moretti et al. (2010). WT and MUT plasmids 
were mixed with various ratios: 1:0, 8:1, 4:1, 2:1, 1:1, 1:2, 1:4, 1:8, and 0:1, respectively, in 
order to form the standard curves. Each plasmid ratio contained 1 ng/µl total plasmid DNA. 
The amounts of wild type and mutant plasmids were calculated according to their plasmid 
DNA concentrations and their proportions in each final plasmid ratio. 
 
Plasmid-derived standard curves were used to evaluate allelic expression differences 
occurring in heterozygous LQTS-mutated cardiomyocytes. Therefore, cDNA samples of 
LQTS-specific cardiomyocytes were produced to be analysed simultaneously together with 
plasmid mixes by qPCR system. The cDNA transcription was occurred as have been 
described above. For detecting expression differences between WT and mutant alleles and 
plasmids, Custom TaqMan® SNP Genotyping Assays (Applied Biosystems, Life 
Technologies Ltd., Carlsbad, CA, USA) were used due to that they contain different probes 
for wild type and mutant targets labelled with different fluorophores (VIC-labelled probe for 
WT and FAM-labelled probe for MUT). Custom TaqMan® SNP Genotyping Assays were 
obtained from Assay service (Life Technologies Ltd.) and the sequences of primers and 
probes are represented in the table 4. PCR reaction mix contained 7,5 µl 2x TaqMan® 
Universal PCR Master Mix, 0,375 µl Custom TaqMan® SNP Genotyping Assay, and 2,125 
µl DNase-free water. Each PCR reaction consisted of 12 µl PCR reaction mix and 3µl cDNA 
or plasmid DNA. Plasmid mixes and cardiomyocyte cDNA samples were analysed as 
triplicates. The qPCR analyses were performed with 7300 Real-Time PCR System (Applied 
Biosystems, Life Technologies Ltd.) and similar thermal cycler condition was used at 
amplification phase that described above. In addition, pre-run and post-run were performed at 
the beginning and at the end of the qPCR analyses, respectively. The used quantification 
method was absolute quantification enabling formation of allelic discrimination.  
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Table 4. Custom TaqMan® SNP Genotyping Assays used in allelic imbalance determinations 
of LQTS-causing mutations. Probes labelled with VIC fluorophore bind with the sites of the 
wild type alleles within WT plasmids or cardiomyocyte samples, whereas probes with FAM 
fluorophore bind with the mutated sites of the mutant plasmids or mutated alleles of 
cardiomyocytes. Also Assay IDs from Assay service (Life Technologies Ltd.) for each marker 
have been described. 
Target Primer/probe Sequence 5’-3’ Assay ID 
KCNQ1-FinA Forward primer 
Reverse primer 
Probe wild type_VIC 
Probe mutation_FAM 
CCCCCATAGAAAAGAGCAAGGAT 
CTACCTTGTCTTCTACTCGGTTCAG 
CGATCGGCGCCCGC 
ACGATCGACGCCCGC 
AHCS714 
 
KCNQ1-FinB Forward primer 
Reverse primer 
Probe wild type_VIC 
Probe mutation_FAM 
GCTCGGGGTTTGCCCTGAAGG 
GGCAGCATAGCACCTCCA 
CTCATTCAGACCGC 
CGACCTCGGACCGC 
AHGJ2KS  
 
HERG-FinA Forward primer 
Reverse primer 
Probe wild type_VIC 
Probe mutation_FAM 
AGCTGGATCGCTACTCAGAGT 
GCGATGAGCGCAAAGGT 
CACATGAGCAAGAACA 
CACATGAGCGAGAACA 
AH20Z2J  
 
HERG-FinB Forward primer 
Reverse primer 
Probe wild type_VIC 
Probe mutation_FAM 
CCAAGACCTTCCGCCTGAA 
TCCACGTCCACCACCAC 
ACGACTCCCGGGCCGT 
CGACTCCCAGGCCGT 
AH39X8R 
 
4.5.1. Standard curve method for evaluating allelic imbalances 
Allelic imbalances of LQTS-specific cardiomyocytes, containing one of the four Finnish 
founder mutations, were determined with plasmid-derived standard curves. The standard 
curves were plotted log2 of wild type/mutant ratios of plasmids [log2(WT/MUT)] versus 
corresponding ΔCt values (Moretti et al., 2010). The ΔCt values were defined by subtracting 
Ct value of wild type marker from Ct value of mutant marker (ΔCt = Ct (mutant) - Ct (wild 
type)). The Ct values were measured during PCR amplification by qPCR system (7300 Real-
Time PCR System, Applied Biosystems, Life Technologies Ltd.) and stored into 
amplification data of 7300 System SDS software (version 1.4). Amplification data was 
exported to the Microsoft Excel (2010) for further processing and formatting standard curves.   
 
In the plasmid-derived standard curves, ΔCt values for plasmid ratios are represented in 
statistical form of mean ± standard deviation (n=3). Equations and linear regressions (R
2
 
values) were evaluated for all standard curves by using Microsoft Excel (2010). The R
2
 values 
were used to estimate linearities of standard curves. The log2(WT/MUT) values for disease-
specific cDNA samples were calculated from the standard curves’ equations by using their 
mean ΔCt values (n=3). The locations of LQTS-specific cardiomyocyte samples on the 
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standard curve were estimated according to calculated log2(WT/MUT) versus ΔCt values. 
Comparing location of specific cell samples with nearby plasmid ratios on the standard curve, 
allelic imbalances for each studied LQTS-related mutation were investigated.   
4.6. Single-cell gene expression determination 
Capacity of commercially available Single cell-to-CT™ Kit (Ambion®, Life Technologies 
Ltd., Carlsbad, CA, USA) to detect protein expression of essential structural gene, cardiac 
troponin T2 from cardiomyocytes was studied in this experiment. The Single cell-to-CT™ Kit 
is a technology based on qPCR’s ability to quantify gene expression levels via measured 
mRNA levels, and it enable detection of gene expression within a single cell. Cardiac 
troponin T2 (TNNT2) was selected to be a target gene due to its abundant expression in 
cardiomyocytes. Therefore, its detection is more confident in single-cell gene expression 
analysis than cardiac genes having lower expression levels (Bengtsson et al., 2008). RPLP0 
was used as an endogenous reference gene in order to normalize TNNT2 expression.  
 
Cardiac cell line UTA.00208.LQT1 was dissociated into 48-well culture plate to intend that 
every well contain 1-10 beating cardiomyocytes, as manufacturer’s protocol defined sample 
size to be. By using a microscope, well which had two beating UTA.00208.LQT1 cells were 
selected for cell lysis procedure. In addition, two samples having plenty of cardiomyocytes 
from UTA.04311.WTs cell line were used as controls in order to evaluate ability of the 
method to detect gene expression from samples with multiple cells and compare detected 
gene expression results between single cell level and cell population level. Wells that 
contained cells of interest were washed twice with phosphate buffered saline (PBS) in order to 
prevent disruption of culture media for cell lysis procedure. Cell lysis was performed 
according to manufacturer’s protocol by adding Single Cell Lysis mix into the washed wells. 
Cell lysates were collected from the wells to the PCR tubes which were used for further 
procedures of the method.  
 
Testing Single cell-to-CT™ Kit (Ambion®, Life Technologies Ltd.) was performed by 
following manufacturer’s protocol and defined reaction mixes and thermal cycler conditions 
in reverse transcription, pre-amplification and qPCR amplification steps. To perform pre-
amplification of cDNA samples transcribed from cell lysates, 20x TaqMan® Gene Expression 
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Assays (Applied Biosystems, Life Technologies Ltd., Carlsbad, CA, USA) of TNNT2 and 
RPLP0 were pooled at the final concentration of 0,2x. TaqMan® Gene Expression Assays 
were obtained from Assay service (Life Technologies Ltd.) with Assay IDs Hs00165960_m1 
and Hs04189669_g1 for TNNT2 and RPLP0, respectively. Pre-amplified cDNA samples 
were diluted 1:20 with 1x TE Buffer (pH 8.0), and those diluted samples were analyzed by 
7300 Real-Time PCR System (Applied Biosystems, Life Technologies Ltd.) in order to 
quantify expressions of TNNT2 and RPLP0 within used cardiomyocyte samples. Therefore, 
two different PCR reaction mixes were prepared, one contained 20x TaqMan® Gene 
Expression Assay of TNNT2 and the other contained 20x TaqMan® Gene Expression Assay 
of RPLP0. Cell samples (one from UTA.00208.LQT1 and two from UTA.04311.WTs cell 
lines) were analyzed as triplicates and both PCR reaction mixes were used for each sample. 
The qPCR analysis was performed in MicroAmp Optical 96-well reaction plate (Applied 
Biosystems, Life Technologies Ltd.) using 50 µl reaction volume consisted of 10 µl 1:20 
diluted pre-amplified cDNA samples and 40 µl reaction mix. Relative quantitation (ddCt) 
method was used to detect TNNT2 target and RPLP0 endogenous control from cell samples.  
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5. Results 
5.1. Cell line characterization 
The allelic discrimination plot (figure 6.) describes the results from cardiac cell line 
characterization with cell lysis -based TaqMan® Sample-to-SNP™ Kit (Applied Biosystems, 
Life Technologies Ltd.). There are observable differences between analyzed LQT1-specific 
cell line samples (UTA.00208.LQT1) and WT cell line samples (UTA.04311.WTs and 
UTA.04511.WTs) in their locations on the allelic discrimination plot resulting from different 
allelic contents. The LQT1-specific cDNA samples located in the middle of the allelic 
discrimination plot (figure 6.), indicating allelic content of both mutated and wild type alleles. 
Analyzed cDNA samples produced from cardiac WT cell lines were homozygotes, indicating 
that they contained only wild type alleles. Therefore, increased fluorescence intensities were 
measured only from VIC-labelled probes within characterized WT samples during PCR 
amplification. Similar results were observed when multiple LQTS-specific, CPVT-specific 
and WT cell lines were characterized using specific markers for four Finnish founder 
mutations with TaqMan® Sample-to-SNP™ Kit (Applied Biosystems, Life Technologies 
Ltd.) (data not shown).  
 
Figure 6. Allelic discrimination plot of characterized cardiac cell line samples. Samples from 
UTA.04311.WTs and UTA.04511.WTs lines are represented as red circles indicating 
homozygous wild type allelic contents. Heterozygote KCNQ1-FinA mutated cardiomyocytes 
(UTA.00208.LQT1) are represented as green triangles due to detected fluorescence signals 
from both probes included in used TaqMan® Assay. The cDNA samples were analyzed as 
triplicates. Sterile water was used as non-template control (NTC, grey squares) in analyses.  
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5.2. Allelic imbalance determination 
Plasmid-derived standard curve method was used to determine allelic imbalances of LQTS-
specific cardiomyocytes derived from induced pluripotent stem cells as have been previously 
described by Moretti et al. (2010). In this study, allelic imbalances were determined for 
LQTS-causing four Finnish founder mutations characterized in KCNQ1 and KCNH2 genes. 
Therefore, eight different plasmids containing mutant and wild type inserts for all determined 
mutations were generated. To form standard curve, WT and mutant plasmids were mixed with 
various ratios: 1:0, 8:1, 4:1, 2:1, 1:1, 1:2, 1:4, 1:8 and 0:1, respectively (Moretti et al., 2010). 
The plasmid ratios contained only WT (1:0) or MUT (0:1) plasmid were used as controls in 
order to confirm detection specificity of qPCR system during PCR amplification. They were 
not used to form standard curves due to undetermined detection of either wild type or mutant 
target amplification that prevents calculating ΔCt values. In addition, log2(WT/MUT) values 
cannot be calculated when the other plasmid content is lacking. Therefore, plasmid-derived 
standard curves were formed by plotting log2(WT/MUT) values versus ΔCt values defined for 
plasmid mixes 8:1, 4:1, 2:1, 1:1,1:2, 1:4 and 1:8.  
5.2.1. KCNQ1-FinA and KCNQ1-FinB mutations 
The cDNA samples used to determine allelic imbalance of KCNQ1-FinA specific 
cardiomyocytes were produced from cell lines UTA.02201.LQT1 and UTA.00208.LQT1 that 
have been generated from patient-specific iPSCs of two KCNQ1-FinA mutation carriers. To 
evaluate allelic imbalance of KCNQ1-FinB specific cardiomyocytes, cDNA samples were 
produced from cell line UTA.00118.LQT1 generated from patient-specific iPSCs of 
individual who carries KCNQ1-FinB mutation.  
 
The plasmid mixes located on the allelic discrimination plots according to their plasmid ratio 
contents, as expected, in KCNQ1-FinA (figure 7A) and KCNQ1-FinB (figure 7C) specific 
analyses. In the allelic discrimination plot, the y-axis describes fluorescence intensity growth 
originated from FAM-labelled probes, whereas x-axis describes increase of fluorescence 
intensity detected from VIC-labelled probes. Therefore, plasmid mix contained only MUT 
plasmids (0:1) had the highest detected fluorescence intensity of FAM-labelled probes. 
Consistently, plasmid mix contained only WT plasmids (1:0) generated fluorescence signals 
from VIC-labelled probes. The other plasmid mixes (8:1, 4:1, 2:1, 1:1, 1:2, 1:4, and 1:8) were 
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arranged between them according to measured fluorescence intensities from both probes 
depending on WT and MUT plasmid proportions (figure 7A, 7C).  
 
The allelic discrimination plot can be used for predicting allele-specific expression occurring 
in analyzed cardiomyocyte samples by comparing their locations with nearby plasmid mixes 
with known allelic contents. In the KCNQ1-FinA specific analysis, all mutant cDNA samples 
clustered between 1:1 and 2:1 (WT:MUT) plasmid mixes but few of them had slightly lower 
fluorescence intensities of FAM fluorophore as compared to nearby plasmid mixes (figure 
7B). Relatively similar clustering was observed with KCNQ1-FinB specific cDNA samples 
within fluorescence intensity curve made by KCNQ1-FinB specific plasmid mixes (figure 
7D). However, allelic discrimination plot is only rough method to confirm that heterozygote 
cardiomyocytes locate among heterozygote plasmid mixes, and therefore, it cannot be used 
directly for determining allelic expression variation of LQTS-mutated cardiomyocytes. For 
that reason, standard curves [log2(WT/MUT) vs. ΔCt] were formed for evaluating allelic 
imbalances of KCNQ1-FinA and KCNQ1-FinB specific cardiomyocyte. 
 
Standard curve formed by KCNQ1-FinA specific plasmid mixes was used for determining 
allelic expression variation of KCNQ1-FinA specific cardiomyocytes (figure 8). Two 
different cardiac cell lines UTA.02201.LQT1 and UTA.00208.LQT1 contained mutation of 
interest were used for determination. The equation defined for standard curve (y = 0,3528x + 
2,4867, where  y = log2(WT/MUT) and x = ΔCt) was used to calculate log2(WT/MUT) values 
for specific cardiomyocyte samples by using their mean ΔCt values (n =3) counted from 
qPCR measured Ct values. For UTA.02201.LQT1-derived cardiomyocytes the calculated 
log2(WT/MUT) values was 1,475, indicating that they have location between 2:1 and 4:1 
(WT:MUT) plasmid mixes on the standard curve (figure 8.). By using the same standard 
curve equation, log2(WT/MUT) value was defined to be 1,577 for UTA.00208.LQT1-derived 
cardiomyocytes. Therefore, they have also location between 2:1 and 4:1 plasmid mixes on the 
standard curve, but slightly closer to 4:1 plasmid mix than UTA.02201.LQT1 cardiomyocytes 
(figure 8.). Due to that defined log2(WT/MUT) values for both cardiomyocyte samples ranged 
approximately 0,5 between log2(WT/MUT) values of 2:1 and 4:1 plasmid mixed, it was 
decided to determine theoretical log2(WT/MUT) value for 3:1 plasmid mix that resulted in 
1,58. By comparing log2(WT/MUT) values of cardiomyocyte samples with log2(WT/MUT)
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Figure 7. Allelic discrimination plots formed during allelic imbalance analyses of KCNQ1-
FinA and KCNQ1-FinB specific cardiomyocytes. Red circles represent plasmid mixes 
contained only WT plasmid (1:0), while plasmid mixes contained only MUT plasmids (0:1) 
are described by blue diamonds. Green triangles symbolize plasmid mixes 1:1, in which 
allelic content of WT and MUT alleles is equal. Other plasmid mixes are represented by black 
crosses in order to avoid mixing with differently symbolized plasmid mixes. Non-template 
control is marked by grey square. All plasmid mixes and cardiomyocyte samples were 
analyzed as triplicates but in the figures one replicate from each sample is represented for 
clarity. (A) Allelic discrimination plot of KCNQ1-FinA specific plasmid mixes. (B) KCNQ1-
FinA specific cardiomyocytes are located among plasmid mixes. The samples are separated 
from plasmid mixes with black boundaries in order to prevent mixing with plasmid mix 
samples having same symbols. (C) Allelic discrimination plot of KCNQ1-FinB specific 
plasmid mixes. (D) Locations of KCNQ1-FinB specific cardiomyocyte samples among 
plasmid mixes are separated with boundaries. 
 
value of 3:1 plasmid ratio, it was observed relatively small differences in the defined values. 
Thus, according to these results allele-specific expression variation is occurring within both 
analyzed KCNQ1-FinA mutated cardiomyocytes (UTA.02201.LQT1 and UTA.00208.LQT1) 
and the allelic expression ratios are 3:1, indicating that wild type allele is expressed 3-fold as 
compared to mutant allele expression. 
 
The allelic imbalance determination of KCNQ1-FinB specific cardiomyocytes were examined 
from standard curve made by KCNQ1-FinB specific plasmid mixes (figure 8.). As described 
A B 
C D 
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above in KCNQ1-FinA determination, the standard curve equation (y = 0,2048x + 1,6727) 
was used to define log2(WT/MUT) values for KCNQ1-FinB specific cardiomyocyte samples 
generated from UTA.00118.LQT1 cell line. Four distinct cell samples were generated from 
the same cell line, and observed allelic imbalance results between them were convergent. In 
this section, results from two samples are represented in details in the figure 8. The calculated 
log2(WT/MUT) values for those cardiomyocyte samples were 1,484 and 1,376, indicating that 
they located between 2:1 and 4:1 (WT:MUT) plasmid mixes, slightly closer to 2:1 plasmid 
mix, on the standard curve (figure 8.). When their log2(WT/MUT) values were compared with 
theoretical 3:1 plasmid mix (1,58), smaller differences were observed between them, as was 
also occurred in the allelic imbalance determination of KCNQ1-FinA. Therefore, the detected 
allelic expression variation in these KCNQ1-FinB specific cardiomyocytes 
(UTA.00118.LQT1) results in three-fold expression of wild type allele as compared to mutant 
allele expression.  
5.2.2. HERG-FinA and HERG-FinB mutations 
Allelic expression variation of HERG-FinA and HERG-FinB specific cardiomyocytes were 
evaluated similarly as described above in the allelic imbalance determination of KCNQ1 
mutations. Mutation specific cDNA samples for HERG-FinA determination were generated 
from LQT2-specific cell lines UTA.03412.LQT2 and UTA.03810.LQT2. Thus, two different 
HERG-FinA specific cardiac cell lines derived from iPSCs of two mutation carriers were used 
for determination. LQT2-specific cardiac cell line used to evaluate allelic imbalance of 
HERG-FinB specific cardiomyocytes was UTA.00525.LQT2. 
 
Allelic discrimination plots of plasmid mixes of both HERG mutations formed curves 
according to their wild type and mutant allelic contents (figure 9A, 9C). Therefore, all LQTS-
specific plasmid mixes prepared to this allelic imbalance study produced similar allelic 
discrimination results (figure 7A, 7C, 9A, 9C), indicating that their wild type and mutant 
insert proportions were desired and suitable for reliable formatting standard curves. As can be 
seen from the allelic discrimination plot containing plasmid mixes and HERG-FinA specific 
cDNA samples (figure 9B), the clustering of cDNA samples among curve made by plasmid 
mixes differ from observed clustering of KCNQ1-FinA and KCNQ1-FinB specific samples 
on their allelic discrimination plots (figure 7B, 7D). The HERG-FinA cDNA samples 
(generated from UTA.03412.LQT2 and UTA.03810.LQT2 cell lines) clustered between 1:1
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Figure 8. Allelic imbalance determinations of KCNQ1-FinA and KCNQ1-FinB specific 
cardiomyocytes by using plasmid-derived standard curve method. Plasmid mixes (8:1, 4:1, 
2:1, 1:1, 1:2, 1:4, and 1:8) are symbolized with black diamonds in the figures. In KCNQ1-
FinB standard curve, the 1:8 plasmid mix was not involved in standard curve formation due to 
the undetected fluorescence signals of VIC fluorophore. The ΔCt values for plasmid mixes 
are represented in statistical form of mean ± standard deviation (n=3). Allelic imbalance of 
KCNQ1-FinA specific cardiomyocytes was determined from two cardiac cells lines: 
UTA.00208.LQT1 marked by red triangle and UTA.02201.LQT1 marked by blue square on 
the standard curve. One KCNQ1-FinB specific cell line UTA.00118.LQT1 was used to 
determine allelic expression variation. Two UTA.00118.LQT1 samples are represented with 
green cycles on the standard curve.  
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and 1:2 (WT:MUT) plasmid mixes, indicating that allelic expression variation may be 
different within HERG-FinA mutated cardiomyocytes as compared to cardiomyocytes with 
specific KCNQ1 mutations. The allelic discrimination plot of HERG-FinB specific 
determination (figure 9D) revealed that all analyzed samples, including control and HERG-
FinB specific cardiac cell samples, were clustered around non-template control (NTC) 
samples. This was observed to occur in three different qPCR analyses by using re-transcribed 
HERG-FinB cDNA samples (generated from UTA.00525.LQT2) and control samples which 
amplification had been verified in earlier allelic imbalance determinations with qPCR system 
(data not shown). For this reason, allele-specific expression analysis could not perform for 
HERG-FinB specific cardiomyocytes. 
 
Figure 9. Allelic discrimination plots of HERG-FinA and HERG-FinB mutations. Used 
symbols are similar with the allelic discrimination plots of KCNQ1 mutations described in the 
previous section. (A) Allelic discrimination plot of HERG-FinA specific plasmid mixes. (B) 
Heterozygote HERG-FinA specific cardiomyocytes locate among plasmid mixes. (C) Allelic 
discrimination plot of HERG-FinB specific plasmid mixes. Two replicates are represented in 
the figure. (D) Locations of HERG-FinB specific cardiomyocyte samples and control samples 
on the allelic discrimination plot are beside with non-template control samples. 
  
Standard curve formed by HERG-FinA specific plasmid mixes was used for determining 
allelic expression variation of HERG-FinA specific cardiomyocytes (figure 10.). Standard 
A B 
C D 
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curve equation (y = 0,6034x + 1,0161) was used to define locations of HERG-FinA cDNA 
samples on the standard curve. The calculated log2(WT/MUT) values for UTA.03412.LQT2 
and UTA.03810.LQT2 samples were -0,2579 and -0,3878, respectively, resulted in locations 
between 1:1 and 1:2 (WT:MUT) plasmid mixes. According to these values, it was suggested 
that mutant samples locate closer with 1:1 plasmid mixes on the standard curve, but ΔCt 
values defined for them were closer with mean ΔCt value defined for 1:2 plasmid mix. 
Therefore, they locate in vicinity with 1:2 plasmid mix in the figure 10. The plasmid-derived 
standard curve revealed that allele-specific expression is also occurring within HERG-FinA 
specific cardiomyocytes, but it differ significantly from the allelic imbalances observed for 
KCNQ1-FinA and KCNQ1-FinB specific cardiomyocytes. According to this allelic imbalance 
determination, mutant allele can be expressed slightly higher than wild type allele within 
HERG-FinA specific cardiomyocytes, but the allelic expression difference is not remarkable. 
 
Figure 10. Allelic imbalance of HERG-FinA specific cardiomyocytes. The allelic imbalance 
of two different HERG-FinA specific cell samples from 03412.LQT2 (light red square) and 
03810.LQT2 (light green triangle) cell lines were determined by using HERG-FinA specific 
standard curve. Locations of HERG-FinA samples were calculated from the equation of 
standard curve by using ΔCt values determined from amplification data.  
 
5.3. Single-cell gene expression experiment 
The amplification plot for low cell number sample (UTA.00208.LQT1) (figure 11A) revealed 
that detection ability of Single cell-to-CT™ Kit (Ambion®, Life Technologies Ltd.) was not 
sufficient to detect amplification of TNNT2, although the pre-amplification was performed 
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before qPCR analysis and the selected target TNNT2 is abundantly expressed in functional, 
beating cardiomyocytes. The amplification of endogenous reference, RPLP0 was, however, 
detected during qPCR analysis (figure 11A) but the amplification initiated in the late PCR 
cycles, approximately during PCR cycle 32 within UTA.00208.LQT1 samples. It indicates 
that the amount of RPLP0 template have been low. Amplifications of both targets, TNNT2 
and RPLP0, were detected to occur within control samples (UTA.04311.WTs), as can be 
observed from their amplification plots (figure 11B, 11C). Although both targets were 
amplified in these control samples containing multiple cardiomyocytes the amplifications of 
TNNT2 were relatively poor, detected to initiate during PCR cycles 28 and 35; whereas 
RPLP0 amplification initiated during PCR cycles 21 and 27. According to these results, it 
suggested that some technical factors related to the used method might cause observed 
amplification differences between low cell number sample (UTA.00208.LQT1) and multiple 
cell samples (UTA.04311.WTs) leading to undetected and reduced TNNT2 amplifications, 
respectively.  
 
 
 
 
A  B 
C Figure 11. Amplification plots representing 
TNNT2 and RPLP0 amplifications during 
single-cell gene expression analysis.          
(A) UTA.00208.LQT1 sample contained 2 
beating cells. (B, C) UTA.04311.WTs cell 
line was used to generate control cell samples 
containing multiple cells. 
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6. Discussion 
This study demonstrated the capacity of quantitative real-time PCR to characterize specific 
gene expression features within iPSC-derived LQTS-specific cardiomyocytes. Three different 
experiments were performed using qPCR for analyzing either amplification of desired target 
genes or their allelic expression differences. The cells that were used in these experiments 
were heterozygous LQTS-specific cardiomyocytes containing four founder mutations in order 
to evaluate disease features occurring among Finnish population. All cardiomyocytes were 
differentiated from patient-specific induced pluripotent stem cells and their functionalities 
were characterized by evaluating expression of cardiac specific markers, such as cardiac 
troponin T2, α-actinin, myosin heavy chain and connexin-43, and  electrophysiological 
features, including delayed repolarization phase and reduced K
+
 ion currents, with MEA and 
patch clamp technology (Lahti et al., 2012). In addition, the control cardiomyocytes were 
generated from iPSCs of healthy individuals and their functionalities were verified similarly 
than was done for disease-specific cardiomyocytes.  
6.1. Cell line characterization by using cell lysis -based method 
In general, cell line characterization is performed by extracting total DNA or transcribing 
cDNA from isolated RNA of cell lines to be genotyped. However, nowadays many methods 
for cell characterization allow use of cell lysate directly for qPCR analysis with appropriate 
markers to perform amplification and detection of desired gene targets (Fox et al., 2012). 
Lysis release total DNA contents of lysed cell samples to be available for PCR amplification 
and therefore, it reduces the lack of DNA target templates that has been related to DNA 
extraction methods. In addition, cell lysis procedure facilitates and makes characterization 
faster due to that previously required DNA extractions are not necessitated before gene 
expression analysis with qPCR. Furthermore, the risk of potential contaminations and failures 
could occur during DNA extraction or cDNA transcription decrease. Especially cell lysis 
techniques are useful when gene expression profiles of low-sized or single cell samples are 
evaluated (Bengtsson et al., 2008).  
 
Using TaqMan® Sample-to-SNP™ Kit (Applied Biosystems, Life Technologies Ltd.) to 
characterize LQT1-specific cardiac cell line contained KCNQ1-FinA mutation and two wild 
type cardiac cell lines, visible differences between LQT1-specific samples and WT samples 
were observed from their arrangements on the allelic discrimination plot caused by their 
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different allelic contents. According to the results of this experiment and results received from 
larger cell line characterization containing LQTS- and CPVT-specific lines (data not shown), 
cell lysis -based method was observed to be suitable for characterizing cardiac cell lines and 
its application can be expanded to characterize genetic contents of multiple cardiac disease-
specific cell lines simultaneously in a routine manner. Non-lysed cellular components can 
disrupt qPCR analysis (Fox et al., 2012) but any disruption was not detected in these 
characterizations due to that analyzed sample sizes were relatively high, and therefore 
sufficient amount of target templates were present in PCR reactions although the cell lysis 
would not have been complete. Previously, there has been shown that TaqMan® Sample-to-
SNP™ Kit (Applied Biosystems, Life Technologies Ltd.) have similar efficiency to detect 
specific SNPs than qPCR analysis performed from cell samples which DNAs has been 
isolated with conventional DNA extraction procedure (Nielsen et al., 2012), indicating that 
cell lysis -based methods are as accurate as conventional methods to detect specific genetic 
features within different cell types. 
6.2. Allelic imbalance determinations of LQTS founder mutations 
High phenotypic variation has been associated with long QT syndrome and typically disease 
phenotype varies even among family members carrying the same LQTS-causing mutation 
(Fodstad et al., 2004). Furthermore, approximately 50 % of diagnosed LQTS patients are 
completely asymptomatic (Toivonen et al., 2008) or have experienced minor cardiac events, 
such as occasional palpitations (Lahti et al., 2012). Due to that significant phenotypic 
variation it has been suggested that some genetic or non-genetic factors cause the variation 
among LQTS patients (Piippo et al., 2001; Fodstad et al., 2004). Allele-specific expression 
variation caused by epigenetic modifications has been considered to be potential factor 
underlying variable phenotypes (Saenen and Vrints, 2008) because it have been confirmed 
that allelic expression variation within human genes is relatively common and affect 
development of human phenotypes (Lo et al., 2003; Buckland, 2004). In addition, it has been 
previously shown that allele-specific expression can promote disease development (Chen et 
al., 2008). To evaluate impact of allele-specific expression on variable LQTS-related 
phenotype, the plasmid-derived standard curve method was used to determine allelic 
imbalances of cardiomyocytes specific for four Finnish founder mutations. The allelic 
imbalance determinations revealed that KCNQ1-FinA and KCNQ1-FinB specific 
cardiomyocytes expressed normal KCNQ1 alleles with higher magnitude than corresponding 
mutant alleles leading to observed allelic proportions 3:1 (WT:MUT) in both cases. This 
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indicated that expressions of wild type alleles are three-fold higher than the expressions of 
mutated alleles within these LQT1-specific cardiomyocytes (UTA.02201.LQT1, 
UTA.00208.LQT1 and UTA.00118.LQT1). 
 
The observed allelic imbalances for KCNQ1 mutations differed from the previous allelic 
imbalance study performed using LQT1-specific cardiomyocytes contained heterozygous 
KCNQ1 mutation, R190Q (Moretti et al., 2010) in which equal expressions of wild type and 
R190Q-mutated alleles (1:1) were observed by using similar plasmid-derived standard curve 
method that has been used in this study. The R190Q mutation locates in cytoplasmic loop 
between transmembrane S2 and S3 segments (Moretti et al., 2010), whereas in contrast, 
KCNQ1-FinA (G589D) and KCNQ1-FinB (IVS7-2A>G) have locations in intracellular C-
terminal end of the α-subunit (Fodstad et al., 2004). These both regions are related to highly 
pathogenic mutations due to that their defects affect significantly to channel functions 
(Giudicessi and Ackerman, 2012). The mechanisms identified from R190Q and G589D 
mutations are affect dominant negatively for protein trafficking (Moretti et al., 2010) and 
subunit assembly ability (Piippo et al., 2001), respectively. KCNQ1-FinB causes larger 
structural defect to α-subunit due to amino acid insertion that lead to complete loss of channel 
function (Fodstad et al., 2006). Thus, these KCNQ1 mutations impair critically α-subunits’ 
functions that result in reduction of IKs current through KCNQ1 channels, but their effects on 
current amplitude have been shown to be different. Moretti et al. (2010) observed that the IKs 
current reduced approximately 75 % in R190Q-mutated cardiomyocytes when were compared 
with control cardiomyocytes. As it have previously suggested that dominant negative effect of 
LQTS-causing mutations may cause more than 50 % reduction of the affected ion current, 
although wild type and mutant alleles are expressed equally within cells (Bezzina and Wilde, 
2007). The observed reductions of IKs currents in KCNQ1-FinA specific (Saucermann et al., 
2004) and KCNQ1-FinB specific (Fodstad et al., 2006) cardiomyocytes have been about 50 % 
and 28 %, respectively. The reduction of IKs current in KCNQ1-FinB specific cardiomyocytes 
(Fodstad et al., 2006) is consistent with the allelic imbalance results observed in this study for 
KCNQ1-FinB specific cardiomyocytes. However, it can be suggested that allelic ratio 3:1 
occurred also within KCNQ1-FinA specific cardiomyocytes would produce less than 50 % 
current reduction that is usually related to equal allelic expression. Ion current reduction is, 
however, cell line -specific variable due to that cardiac cell lines are generated from patient-
specific cells having their unique phenotypic features. Therefore, these measured IKs current 
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reductions (Saucermann et al., 2004; Fodstad et al., 2006) do not represent reliable the 
reductions occurring within cell lines used in this study (UTA.00208.LQT1, 
UTA.02201.LQT1 and UTA.00118.LQT1) although they contained same mutations.  
 
On the other hand, it has been suggested that milder phenotypic effects of founder mutations 
within Finnish population have allowed their enrichment (Piippo et al., 2001). This allele-
specific expression determination may support the fact that higher expression of wild type 
allele and suppressed expression of mutant allele can lead to milder phenotypic effects. In this 
study, used cardiomyocytes specific for KCNQ1-FinA and KCNQ1-FinB were generated 
from symptomatic patients who have prolonged QT intervals and experienced cardiac 
symptoms. In addition, patient-specific iPSC-derived cardiomyocytes have shown prolonged 
APDs and abnormal beating behaviors (Kiviaho et al., submitted). It is known that these both 
mutations are loss-of-function mutations and have dominant negative effects on channel 
function (Fodstad et al., 2004). Therefore, the detected allelic expression ratio 3:1 is 
suggested to cause suppressed expression of mutant allele resulting in production of higher 
amount of normal α-subunits which are able to form more functional repolarizing K+ ion 
channels and thus phenotypic effects would be milder, such as increased IKs current amplitude 
and decreased arrhythmogenic susceptibility as compared with LQT1-specific 
cardiomyocytes containing rare mutations (Moretti et al., 2010). However, further 
investigations are required to confirm this hypothesis by using larger study populations 
containing cardiomyocytes specific for founder mutations and more rare LQT1-causing 
mutations which have similar effects to channel function. Therefore comparing allelic 
imbalances determined for founder mutations and rare mutations can reveal the potential of 
allelic expression variation to affect severities of disease phenotypes. Furthermore, this allelic 
imbalance method could be useful for evaluating impact of allele-specific expression on 
development of LQTS-related cardiac events by comparing cardiomyocytes derived from 
symptomatic and asymptomatic mutation carriers.  
 
The allelic imbalance determination of HERG-FinA specific cardiomyocytes revealed that 
mutant alleles were slightly higher expressed than wild type alleles within used HERG-FinA 
specific cardiac cell lines (UTA.03412.LQT2 and UTA.03810.LQT2) but the expression 
variation between alleles was not thought to be significant. It was complicated to determine 
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allelic imbalance accurately due to that defined log2(WT/MUT) values were closer with 
log2(WT/MUT) value for 1:1 plasmid mix, while the defined ΔCt values were closer with ΔCt 
value for 1:2 plasmid mix (WT:MUT). Thus, the locations of specific cell samples were 
nearby 1:2 plasmid mix on the standard curve, although the allele-specific expressions were 
not supposed to be such variable due to log2(WT/MUT) values calculated from standard curve 
equation. The HERG-FinA mutation increases activation and deactivation rates of rapidly 
activating delayed rectifier K
+
 ion channel and thereby reduce IKr current and delay 
repolarization (Piippo et al., 2000), indicating that it has significant effect on disease 
phenotype development. The used cDNA samples of HERG-FinA specific cardiomyocytes 
were generated from isolated RNAs of embryonic bodies and therefore other cell types 
presented in EBs might have disrupt detection and amplification of target HERG-FinA 
mutated alleles and corresponding wild type alleles within cardiomyocytes in qPCR analyses, 
leading to unspecific amplification of especially mutant allele. However, it can be possible 
that stochastic allelic expression variation (Elowitz et al., 2002) occurs within these HERG-
FinA mutated cardiomyocytes and causes slightly overexpression of mutant alleles in a 
randomly manner. This study could not manage to show that HERG-FinA mutation may 
cause milder disease phenotype (Piippo et al., 2001) due to the observed allelic expression 
variation resulted in slightly higher mRNA levels of mutant α-subunits. 
 
HERG-FinB specific allelic imbalance were not able to determined due to technical obstacles 
occurred during qPCR analyses that led to undetected amplification of HERG-FinB specific 
cardiomyocyte and control samples, although HERG-FinB specific plasmid mixes were 
amplified appropriately. It suggested that used TaqMan® Assay specific for HERG-FinB 
mutation did not work properly because control samples used in previous allelic imbalance 
determinations were amplified in those analyses as expected (data not shown) but they were 
not amplified in this determination and resulted in clustering close to non-template controls 
on the allelic discrimination plot. Possibly, reduced efficiency of HERG-FinB specific 
TaqMan® Assay causes decreased amplification and detection of target templates among 
various different templates included in cDNA samples, whereas detection of plasmid mixes is 
sufficient when disrupting distinct DNA templates are not presented in PCR reactions.  
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This allelic imbalance study detected only mRNA levels of wild type and mutant alleles and 
thus, observed allelic variations describe variations occurred between WT and mutant 
transcripts. According to measured mRNA transcripts for KCNQ1-FinA and KCNQ1-FinB 
specific cardiomyocytes, it suggested that 75 % of α-subunits are normal and 25 % are 
mutated α-subunits with defective function. Therefore, higher amount of functional channel-
forming α-subunits are generated in these cardiomyocytes and adverse influences of dominant 
negative mutations reduce. In addition, when allele-specific expression is 3:1 (WT:MUT), the 
probability for K
+
 ion channel consisting only wild type α-subunits is 32 % (Kiviaho et al., 
submitted), while the equal allelic expression produce probability of 6 % for channel 
containing only wild type α-subunits, as can be suggested to occur in HERG-FinA specific 
cardiomyocytes. However, translational processes and posttranslational modifications of 
proteins affect the final composition of WT and mutant α-subunits in cardiomyocytes and 
therefore, these mRNA-based allelic imbalance results are only estimations of potential 
proportions of α-subunits. 
 
Allelic expression variation studies performed previously have observed that allele-specific 
expression is relatively common in many human genes (Lo et al., 2003). The cellular 
mechanisms causing gene expression variations are, however, highly unknown. It has been 
suggested that epigenetic modifications, such as hypermethylation of promoter regions or 
genetic alterations of non-coding regions may lead to higher expression of either allele 
(Buckland, 2004; Chen et al., 2008; Shen et al., 2011). The identified transcription start sites 
and promoter regions for KCNQ1 and KCNH2 genes (Luo et al., 2008) may enhance further 
studies to investigate epigenetic mechanisms underlying allele-specific expression revealed 
by this present allelic imbalance determinations. For example, high CpG island content of 
KCNQ1 promoter region (Luo et al., 2008) enables evaluating effects of their potential 
methylation on observed allelic ratio 3:1 within KCNQ1-FinA and KCNC1-FinB specific 
cardiomyocytes.  
 
Linear regression (R
2
) values were defined for each formed plasmid-derived standard curve 
by using Microsoft Excel (2010) in order to estimate correlation between log2 value for 
plasmid ratio of wild type and mutant inserts (y-axis) and ΔCt values detected by qPCR 
system (x-axis). If standard curve’s R2 value is 1,0 the variables are completely correlating. 
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The defined R
2
 values for KCNQ1-FinA, KCNQ1-FinB and HERG-FinA specific standard 
curves were 0,9322, 0,9844 and 0,9193, respectively. These observed nonlinearities might be 
caused by nonspecific hybridization of mutant probes of used TaqMan® Assays during PCR 
amplification phases in qPCR analyses. It can be observed from all allelic discrimination plot 
represented in this study, including cell line characterization and allelic imbalance 
experiments, that fluorescence signal intensities originated from FAM-labelled probes 
hybridized with mutant alleles (y-axis) are significantly higher as compared to fluorescence 
signal intensities from VIC-labelled probes bound with WT alleles (x-axis). The detected 
fluorescence intensity differences between mutant and wild type probes are approximately 
three-fold in the every allelic discrimination plot. Therefore, the mutant plasmids and mutant 
alleles within analyzed cDNA samples were detected with higher magnitudes than 
corresponding wild type fragments. In KCNQ1-FinA allelic imbalance determination (figure 
8.) was observed that plasmid mixes containing higher or equal amount of WT plasmid than 
mutant plasmid (8:1, 4:1, 2:1, and 1:1) did not align linear with the plasmid mixes containing 
higher amount of mutant plasmid (1:2, 1:4, and 1:8), influencing directly for Ct values 
determined for wild type inserts during amplification and therefore calculating of ΔCt values 
used for standard curve formation. The nonspecific binding of mutant probes with wild type 
templates was tried to reduce by increasing annealing temperature from 60 °C to upwards but 
even one degree lifting to 61 °C impacted adversely on amplification of all plasmid mixes 
(data not shown). Thus, further allelic imbalance determinations were decided to perform at 
annealing temperature of 60 °C.  
 
The linear regression of KCNQ1-FinB specific standard curve was slightly better (R
2
 = 
0,9844) than linear regressions of KCNQ1-FinA and HERG-FinA specific standard curves 
(R
2
 = 0,9322 and R
2
 = 0,9193, respectively) but still the R
2
 value was not as good as the 
standard curve can be considered as linear. However, nonspecific hybridization of mutant 
probes occurred in KCNQ1-FinA and HERG-FinA specific analyses were more significant 
than occurred in KCNQ1-FinB specific analysis, reflecting better linear alignment of plasmid 
mixes on the standard curve. The nonspecific binding, however, led to undetected Ct values 
of WT plasmids in the 1:8 plasmid mixes and therefore the standard curve was generated 
using only the remaining plasmid ratios. The amplification data of HERG-FinA specific 
determination revealed that FAM fluorophore has produced fluorescent signals even within 
non-template controls and control cDNA samples, suggesting that mutant probes might have 
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degraded in used TaqMan® Assay leading to detected fluorescence signals from free FAM 
fluorophores rather than their nonspecific binding during the qPCR analysis. Due to this 
observation the allelic imbalance results of HERG-FinA specific cardiomyocytes are not 
reliable and thus, further studies are required for its evaluation.  
6.3. Evaluating TNNT2 expression at low cell level 
Cell populations are commonly heterogeneous resulting in different behavioral and functional 
features of individual cells among the population (Kalisky et al., 2011; Narsinh et al., 2011; 
Ståhlberg et al., 2011). For evaluating heterogeneity within cardiomyocyte population, Single 
cell-to-CT™ Kit (Ambion®, Life Technologies Ltd.) was used to quantify relative gene 
expression of cardiac troponin T2 (TNNT2) within cardiomyocyte samples contained two 
beating cells (UTA.00208.LQT1). The TNNT2 amplification was not detected from low-sized 
samples although amplification of housekeeping gene, RPLP0 occurred. Similar results were 
detected from cardiomyocyte sample containing seven beating cells (data not shown), 
indicating that the used method was not efficient to detect specific gene expression within 
defined 1-10 cell sample size. To evaluate reasons for the failed detection of abundantly 
expressed TNNT2, few potential causes were arisen. Pre-amplification was performed by 
using pooled TNNT2 and RPLP0 markers that might have led to competition between them 
during PCR amplification and production of higher amount of amplified RPLP0 than TNNT2 
target (Peixoto et al., 2004). For this reason, the template amounts of TNNT2 may have been 
extremely low in qPCR analyses and therefore detection ability of qPCR system has not been 
sufficient to measure its amplification. For future single-cell gene expression studies, primer 
competition has to be evaluated before qPCR analyses (Ciriza et al., 2012). If any competition 
between used markers is observed, other housekeeping gene has to select to normalize 
expression of target gene. For example, PPIA could be an appropriate choice to be 
housekeeping gene for normalizing TNNT2 expression within cardiomyocytes due to that it 
has similar reaction efficiency than RPLP0 has (Kosloski et al., 2009). In addition, before 
qPCR analysis the pre-amplified samples were diluted 1:20 according to manufacturer’s 
protocol that could have been too much for the low-sized samples leading to further reduction 
of template amount. In next time, single-cell gene expression analysis using Single cell-to-
CT™ Kit (Ambion®, Life Technologies Ltd.) is preferred to perform with non-diluted or less 
diluted single cell samples in order to enhance detection efficiency of the method. However, 
TNNT2 amplifications were detected from control cardiomyocyte samples contained plenty 
of cells, which excluded the doubt about nonfunctional TaqMan® Assay of TNNT2. It was, 
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however, observed that amplifications were relatively low than could be assumed for 
abundantly expressed gene (Bengtsson et al., 2008). Therefore, results from controls were in 
consistent with observed fact that amount of TNNT2 template may have decreased during this 
single-cell gene expression analysis, resulting in higher amplifications of RPLP0 gene within 
all analyzed cardiomyocytes. 
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7. Conclusions 
In conclusion, the quantitative real-time PCR is appropriate method for characterizing specific 
genetic features of LQTS-specific cardiomyocytes derived from patient-specific induced 
pluripotent stem cells. Cardiac cell lines can be characterized using cell lysis -based 
genotyping methods without any observed disruptions caused by non-lysed cellular 
components. Therefore, the method can be used for characterize distinct cardiac disease-
specific cell lines effectively and accurately. In this study performed single-cell gene 
expression analysis was not succeeded and thus further studies are required before gene 
expression can be evaluated within a single cardiomyocyte.  
 
Allelic imbalance determination by using plasmid-derived standard curve method revealed 
that allele-specific expression between wild type and mutant alleles is occurred with 
proportion 3:1 (WT:MUT) within KCNQ1-FinA and KCNQ1-FinB specific cardiomyocytes. 
Therefore, allelic expression variation may be a potential genetic factor affecting phenotypic 
variation related to long QT syndrome. The allelic imbalance occurring within LQT1-specific 
cardiomyocytes containing Finnish founder mutations can also elucidate the presumption that 
founder mutations may cause milder phenotypic effects permitted their enrichment among 
Finnish population.  However, to confirm these hypotheses larger study populations are 
required that contain LQTS-specific cardiomyocytes generated from patients carrying Finnish 
founder mutations and more rare LQTS-associated mutations in order to verify impact of 
allelic imbalance on phenotypic variation and milder phenotypic effects. In addition, allelic 
expression variation’s effect on phenotypic severity can be investigated with determinations 
based on cardiomyocytes generated from symptomatic and asymptomatic patients. 
Furthermore, the plasmid-derived standard curve method represented in this study enables to 
evaluate impacts of allelic expression variations on pathogenesis of other heterozygous 
cardiac disorder that inherent autosomal dominantly way, such as catecholaminergic 
polymorphic ventricular tachycardia (CPVT) and hypertrophic cardiomyopathy (HCM). 
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